WO2023201315A2 - Ophthalmic agent in preservative removal device - Google Patents
Ophthalmic agent in preservative removal device Download PDFInfo
- Publication number
- WO2023201315A2 WO2023201315A2 PCT/US2023/065750 US2023065750W WO2023201315A2 WO 2023201315 A2 WO2023201315 A2 WO 2023201315A2 US 2023065750 W US2023065750 W US 2023065750W WO 2023201315 A2 WO2023201315 A2 WO 2023201315A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymeric matrix
- ophthalmic agent
- emulsion
- solution
- cyclodextrin
- Prior art date
Links
- 239000003732 agents acting on the eye Substances 0.000 title claims abstract description 268
- 229940125702 ophthalmic agent Drugs 0.000 title claims abstract description 268
- 239000003755 preservative agent Substances 0.000 title claims abstract description 176
- 230000002335 preservative effect Effects 0.000 title claims abstract description 153
- 239000011159 matrix material Substances 0.000 claims abstract description 273
- 239000000243 solution Substances 0.000 claims abstract description 177
- 239000000839 emulsion Substances 0.000 claims abstract description 165
- 239000000725 suspension Substances 0.000 claims abstract description 163
- 230000000694 effects Effects 0.000 claims abstract description 116
- 238000000034 method Methods 0.000 claims abstract description 108
- 230000002209 hydrophobic effect Effects 0.000 claims description 157
- 229920000858 Cyclodextrin Polymers 0.000 claims description 128
- 230000004410 intraocular pressure Effects 0.000 claims description 57
- -1 latanoprostbunod Chemical compound 0.000 claims description 55
- 229920002401 polyacrylamide Polymers 0.000 claims description 53
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 51
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 51
- 239000000178 monomer Substances 0.000 claims description 49
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 claims description 48
- 239000008139 complexing agent Substances 0.000 claims description 48
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 46
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 44
- 229960001160 latanoprost Drugs 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 40
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 40
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 claims description 37
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 36
- 239000000017 hydrogel Substances 0.000 claims description 34
- 229960004853 betadex Drugs 0.000 claims description 31
- 229920001577 copolymer Polymers 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 26
- 239000001116 FEMA 4028 Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 229920000098 polyolefin Polymers 0.000 claims description 22
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 21
- 229960004605 timolol Drugs 0.000 claims description 21
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 19
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 18
- 229960002368 travoprost Drugs 0.000 claims description 18
- 206010030043 Ocular hypertension Diseases 0.000 claims description 17
- 229960002470 bimatoprost Drugs 0.000 claims description 17
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 16
- 229920001684 low density polyethylene Polymers 0.000 claims description 16
- 239000004702 low-density polyethylene Substances 0.000 claims description 16
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 15
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 15
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 15
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 15
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims description 14
- 238000004132 cross linking Methods 0.000 claims description 14
- 230000004304 visual acuity Effects 0.000 claims description 13
- 239000011324 bead Substances 0.000 claims description 12
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims description 11
- 229960000722 brinzolamide Drugs 0.000 claims description 11
- 150000003180 prostaglandins Chemical class 0.000 claims description 11
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 claims description 10
- 229960003216 aceclidine Drugs 0.000 claims description 10
- WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 claims description 10
- 229950009210 netarsudil Drugs 0.000 claims description 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 9
- 239000004584 polyacrylic acid Substances 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 229960003679 brimonidine Drugs 0.000 claims description 8
- 239000004703 cross-linked polyethylene Substances 0.000 claims description 8
- 229920003020 cross-linked polyethylene Polymers 0.000 claims description 8
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 8
- 229960003933 dorzolamide Drugs 0.000 claims description 8
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 8
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 229920001155 polypropylene Polymers 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 8
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 7
- 108010036949 Cyclosporine Chemical class 0.000 claims description 7
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 7
- 229960001265 ciclosporin Drugs 0.000 claims description 7
- 229930182912 cyclosporin Chemical class 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical class C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 7
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 description 72
- 238000009472 formulation Methods 0.000 description 64
- 239000002245 particle Substances 0.000 description 36
- 235000002639 sodium chloride Nutrition 0.000 description 33
- 238000005259 measurement Methods 0.000 description 31
- 239000006196 drop Substances 0.000 description 29
- 150000003839 salts Chemical class 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 25
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 229920000642 polymer Polymers 0.000 description 22
- 239000000546 pharmaceutical excipient Substances 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- ZTWTYVWXUKTLCP-UHFFFAOYSA-N vinylphosphonic acid Chemical compound OP(O)(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-N 0.000 description 16
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 229940110775 latanoprost ophthalmic solution Drugs 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 208000010412 Glaucoma Diseases 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 230000035699 permeability Effects 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 238000005057 refrigeration Methods 0.000 description 10
- 239000004971 Cross linker Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 208000023715 Ocular surface disease Diseases 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000011109 contamination Methods 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960001724 brimonidine tartrate Drugs 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 5
- 229960002610 apraclonidine Drugs 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 239000002997 ophthalmic solution Substances 0.000 description 5
- 238000002577 ophthalmoscopy Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- LOVMMUBRQUFEAH-UIEAZXIASA-N Latanoprostene bunod Chemical compound C([C@@H](O)CCC=1C=CC=CC=1)C[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OCCCCO[N+]([O-])=O LOVMMUBRQUFEAH-UIEAZXIASA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 235000010338 boric acid Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 238000005192 partition Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229960005221 timolol maleate Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 3
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 3
- KAKYNGJFPXFCDD-PPHPATTJSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(4r)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1.CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 KAKYNGJFPXFCDD-PPHPATTJSA-N 0.000 description 3
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000001860 Eye Infections Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000003863 ammonium salts Chemical group 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 3
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 229940100654 ophthalmic suspension Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 125000005430 oxychloro group Chemical group 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- KSBKLOORIKSXDP-BWJWWNBBSA-N (2s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol;(4r,6r)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide Chemical compound CCN[C@@H]1C[C@@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 KSBKLOORIKSXDP-BWJWWNBBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010018325 Congenital glaucomas Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 206010012565 Developmental glaucoma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000000495 cryogel Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- HXOLFXRMWWHLMH-UHFFFAOYSA-L disodium boric acid carbonate Chemical compound [Na+].[Na+].OB(O)O.[O-]C([O-])=O HXOLFXRMWWHLMH-UHFFFAOYSA-L 0.000 description 2
- 229940075885 dorzolamide / timolol Drugs 0.000 description 2
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001523 electrospinning Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 229940031098 ethanolamine Drugs 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229950010607 latanoprostene bunod Drugs 0.000 description 2
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 2
- 229960004834 levobunolol hydrochloride Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 2
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 238000002174 soft lithography Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960004458 tafluprost Drugs 0.000 description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWIUTZDMDHAVTP-QGZVFWFLSA-N (R)-betaxolol Chemical compound C1=CC(OC[C@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-QGZVFWFLSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- OOHZIRUJZFRULE-UHFFFAOYSA-N 2,2-dimethylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(C)(C)C OOHZIRUJZFRULE-UHFFFAOYSA-N 0.000 description 1
- BESKSSIEODQWBP-UHFFFAOYSA-N 3-tris(trimethylsilyloxy)silylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C BESKSSIEODQWBP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZUIFJYRNWWNOPB-PPHPATTJSA-N 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)quinoxalin-6-amine;(2s)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 ZUIFJYRNWWNOPB-PPHPATTJSA-N 0.000 description 1
- COCLLEMEIJQBAG-UHFFFAOYSA-N 8-methylnonyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)=C COCLLEMEIJQBAG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 150000000703 Cerium Chemical class 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical class OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000028 Gradient copolymer Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000008522 N-ethylpiperidines Chemical class 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PTQWFLCGYPLVQU-UHFFFAOYSA-M [Na+].CC([O-])=O.OB(O)O Chemical compound [Na+].CC([O-])=O.OB(O)O PTQWFLCGYPLVQU-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 201000000351 arcus senilis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- 229940098085 betagan Drugs 0.000 description 1
- 229940059219 betoptic s Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 150000001661 cadmium Chemical class 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- JFBJUMZWZDHTIF-UHFFFAOYSA-N chlorine chlorite Inorganic materials ClOCl=O JFBJUMZWZDHTIF-UHFFFAOYSA-N 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940025781 combigan Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940069275 cosopt Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- GTBGXKPAKVYEKJ-UHFFFAOYSA-N decyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(C)=C GTBGXKPAKVYEKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SAUMVKNLVQDHMJ-UHFFFAOYSA-N dichlorine trioxide Inorganic materials ClOCl(=O)=O SAUMVKNLVQDHMJ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000004949 exfoliation syndrome Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- SKCKOFZKJLZSFA-FSIIMWSLSA-N fucitol Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO SKCKOFZKJLZSFA-FSIIMWSLSA-N 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940039014 isoptocarpine Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- HNPFPERDNWXAGS-NFVOFSAMSA-N latanoprost free acid Chemical compound C([C@@H](O)CCC=1C=CC=CC=1)C[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O HNPFPERDNWXAGS-NFVOFSAMSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940112534 lumigan Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- CNWVYEGPPMQTKA-UHFFFAOYSA-N n-octadecylprop-2-enamide Chemical compound CCCCCCCCCCCCCCCCCCNC(=O)C=C CNWVYEGPPMQTKA-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
- 230000004386 ocular blood flow Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 201000000041 pigment dispersion syndrome Diseases 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940015676 simbrinza Drugs 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940084765 timolol ophthalmic solution Drugs 0.000 description 1
- 229940034744 timoptic Drugs 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- KMZJRCPGGAQHGC-UHFFFAOYSA-N trisodium boric acid borate Chemical compound [Na+].[Na+].[Na+].OB(O)O.[O-]B([O-])[O-] KMZJRCPGGAQHGC-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229940108420 trusopt Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- ophthalmic solutions, suspensions, and emulsions for reducing intraocular pressure (IOP) in an eye comprise an ophthalmic agent and one or more preservatives to protect against contamination and to allow for long-term storage and use without refrigeration.
- the preservatives in the solution, suspension, and emulsion may cause corneal toxicity, ocular surface disease, irritation, or other unwanted side effects in the affected eye when administered to the affected eye.
- systems and devices for delivering ophthalmic solution, suspension, and emulsion with little to no preservatives while the activity of the ophthalmic agent is maintained even after storage without refrigeration for long durations.
- ophthalmic formulation comprising an ophthalmic agent and a preservative that removes the preservative as the ophthalmic formulation is dispensed while retaining an activity of an ophthalmic agent in the dispensed formulation.
- the formulation as dispensed as described herein can maintain the sterility, reduce the risk for ocular infection, allow for a multi-dose use delivery format that can be stored at room temperature or without a need for refrigeration, while reducing unwanted side effects and maintaining the activity of the ophthalmic agent once delivered to the eye.
- a method for providing a hydrophobic ophthalmic agent comprising: providing a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and providing a polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
- IOP intraocular pressure
- the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- IOP intraocular pressure
- the reduction in the intraocular pressure is measured by applanation tonometry.
- the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
- the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
- a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
- a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w).
- the polymeric matrix is a polymeric hydrogel.
- the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof.
- the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MB AM N,N’-methylenebis(acrylamide)
- TATZ triacrylamido triazine
- SR 351, or SR9035 SR 351
- the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoeth
- the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 -acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- the crosslinked polyacrylamide material is isolated in the form of spherical beads.
- the at least one modifying monomer comprises 2- acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM).
- the solution, suspension, or emulsion further comprises a complexing agent.
- the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
- the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agentforthe polymeric matrix.
- the complexing agent comprises a cyclodextrin.
- the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interiorof the cyclodextrin.
- the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin
- a concentration of the complexing agent is less than 200 micromolar.
- the polymeric matrix comprises an active matrix component and an inactive matrix component.
- the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
- the active polymeric matrix component is a polymeric hydrogel.
- the inactive polymeric matrix component is a polyolefin.
- the polyolefin is a polyethylene, polypropylene or copolymers thereof.
- the polyolefin is a low-density polyethylene (LDPE).
- a method for providing an ophthalmic agent comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removedin the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less th an 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
- the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- IOP intraocular pressure
- the reduction in the intraocular pressure is measured by applanation tonometry.
- the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
- the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
- a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
- a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration ofthe hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w).
- the polymeric matrix is a polymeric hydrogel.
- the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof.
- the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MB AM N,N’-methylenebis(acrylamide)
- TATZ triacrylamido triazine
- SR 351, or SR9035 SR 351
- the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoeth
- the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- the crosslinked polyacrylamide material is isolated in the form of spherical beads.
- the at least one modifying monomer comprises 2- acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM).
- the solution, suspension, or emulsion further comprises a complexing agent.
- the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
- the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix.
- the complexing agent comprises a cyclodextrin.
- the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interiorof the cyclodextrin.
- the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin
- a concentration of the complexing agent is less than 200 micromolar.
- the polymeric matrix comprises an active matrix component and an inactive matrix component.
- the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
- the active polymeric matrix component is a polymeric hydrogel.
- the inactive polymeric matrix component is a polyolefin.
- the polyolefin is a polyethylene, polypropylene or copolymers thereof.
- the polyolefin is a low-density polyethylene (LDPE).
- a method for delivering a hydrophobic ophthalmic agent to an eye of a subject to reduce intraocular pressure comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
- IOP intraocular pressure
- the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- IOP intraocular pressure
- the reduction in the intraocular pressure is measured by applanation tonometry.
- the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
- the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
- a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
- a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agentis between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w).
- the polymeric matrix is a polymeric hydrogel.
- the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof.
- the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 - acrylamido-2-methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MAA methyl methacrylate
- AMPS 2 - acrylamido-2-methylpropane sulfonic acid
- SEM 2 -sulfoethyl methacrylate
- acrylic acid AA
- VP vinylphosphonic acid
- the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- the crosslinked polyacrylamide material is isolated in the form of spherical beads.
- the at least one modifying monomer comprises 2-acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM).
- the solution, suspension, or emulsion further comprises a complexing agent.
- the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
- the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix.
- the complexing agent comprises a cyclodextrin.
- the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin.
- the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin
- a concentration of the complexing agent is less than 200 micromolar.
- the polymeric matrix comprises an active matrix component and an inactive matrix component.
- the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
- the active polymeric matrix component is a polymeric hydrogel.
- the inactive polymeric matrix component is a polyolefin.
- the polyolefin is a polyethylene, polypropylene or copolymers thereof.
- the polyolefin is a low-density polyethylene (LDPE).
- a multi-dosing delivery device for dispensing a hydrophobic ophthalmic agent, the device comprising: a bottle having an extended outlet; a polymeric matrix dispensed within the extended outlet; and a reservoir configured to hold a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative, wherein the polymeric matrix is configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
- the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mm Hg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eyebelow atleast 25, 24, 23, 22, or 21 mmHg.
- IOP intraocular pressure
- the reduction in the intraocular pressure is measured by applanation tonometry.
- the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
- the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
- a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
- a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w).
- a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w).
- a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w).
- the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w).
- the polymeric matrix is a polymeric hydrogel.
- the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof.
- the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MB AM N,N’-methylenebis(acrylamide)
- TATZ triacrylamido triazine
- SR 351, or SR9035 SR 351
- the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoeth
- the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 -acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MAA methyl methacrylate
- AMPS 2 -acrylamido-2 -methylpropane sulfonic acid
- SEM 2 -sulfoethyl methacrylate
- acrylic acid AA
- VP vinylphosphonic acid
- the crosslinked polyacrylamide material is isolated in the form of spherical beads.
- the at least one modifying monomer comprises 2- acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM).
- the solution, suspension, or emulsion further comprises a complexing agent.
- the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
- the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix.
- the complexing agent comprises a cyclodextrin.
- the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interiorof the cyclodextrin.
- the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin
- a concentration of the complexing agent is less than 200 micromolar.
- the polymeric matrix comprises an active matrix component and an inactive matrix component.
- the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
- the active polymeric matrix component is a polymeric hydrogel.
- the inactive polymeric matrix component is a polyolefin.
- the polyolefin is a polyethylene, polypropylene or copolymers thereof.
- the polyolefin is a low-density polyethylene (LDPE).
- FIG. 1 shows a study design for comparing administration of a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) to subjects.
- FIG. 2 shows intraocular pressure (IOP) (mmHg) measured in subjects administered commercially available a formulation comprising latanoprost and a formulation comprising latanoprost removed by a preservative removing device (TC-002) at different time points.
- FIG. 3A shows a study design for comparing administration of a commercially available formulation comprising timolol (with preservative) and a formulation comprising timolol with the preservative removed by a preservative removing device to subjects.
- FIG. 3B is shows mean trough intraocular pressure (IOP) (mmHg) measured at each assessment day in subjects administered a commercially available formulation comprising timolol (with preservative) and a formulation comprising timolol with the preservative removed by a preservative removing device.
- IOP intraocular pressure
- FIG. 4A depicts a study design for comparing administration of a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) to subjects.
- FIG. 4B shows a table of average of average intraocular pressure (IOP) (mmHg) measured at different timepoints in subjects administered a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002). Data were measured for right eye (OD) and left eye (OS).
- IOP intraocular pressure
- FIG. 4C shows a table of average change in intraocular pressure (IOP) (mmHg) measured in subjects administered a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) at different timepoints relative to a baseline of the first time point, day 1 of FIG. 4B.
- IOP intraocular pressure
- FIG. 4D shows average change in intraocular pressure (IOP) (mmHg) measured in subjects administered a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) at different timepoints relative to a baseline of the first time point, day 1 of FIG. 4B.
- IOP intraocular pressure
- Intraocular pressure (IOP) of an eye may become elevated with aging, disease, or injuries, or as a side effect from a medication. Increased IOP occurs when the pressure within the eye exceeds normal limits (e.g., the normal range of 10-21 mmHg). Increased IOP is commonly associated with open -angle glaucoma and ocular hypertension and may result in damage to the optic nerve and/or permanent vision loss if left untreated. Treatment to reduce increased IOP usually includes but is not limited to medication, laser treatments, and/or surgery to decrease fluids and increase drainage in the eye.
- Medications for treating increased IOP often include an ophthalmic active agent and one or more preservatives.
- the preservatives such as benzalkonium chloride (BAK)
- BAK benzalkonium chloride
- the preservatives may cause corneal toxicity, ocular surface disease (OSD), irritation, or other unwanted side effects in the affected eyewhen administered to the affected eye.
- OSD ocular surface disease
- preservative-free ophthalmic formulations may be provided as a single use packet, which can be wasteful.
- the preservative-free ophthalmic formulations maybe susceptible to bacterial, fungal, or viral contamination that can have deleterious effect, including but not limited to infection, vision loss, and/or death.
- ophthalmic solution, suspension, and emulsion with little to no preservatives while maintaining the activity of the ophthalmic agent even after storage without refrigeration for long durations.
- Described herein are methods and devices for dispensing an ophthalmic formulation comprising an ophthalmic agent and a preservative to treat one or more ophthalmic conditions that removes the preservative as the ophthalmic formulation is dispensed while retaining an activity of an ophthalmic agent in the dispensed formulation.
- Provided herein are methods and devices for dispensing an ophthalmic formulation comprising an ophthalmic agent and a preservative through a polymeric matrix that removes preservative from the ophthalmic formulation while retaining the activity of the ophthalmic formulation and providing a sterile formulation that has preservative removed.
- the formulation as dispensed as described herein can maintain the sterility, reduce the risk for ocular infection, allow for a multi-dose use delivery format that can be stored at room temperature or without a need for refrigeration, while reducing unwanted side effects and maintaining the activity of the ophthalmic agent once delivered to the eye.
- the methods and devices provided herein for removal of preservatives from ophthalmic formulations allow for retaining the activity of the ophthalmic formulation (e.g., reduced increased IOP) and while providing a sterile formulation that has preservative removed.
- multi-dosing, preservative removing devices comprising a polymeric matrix configured such that the device maintains an ophthalmic formulation with one or more preservatives and one or more activities of the ophthalmic agent until the ophthalmic formulation is passed through the polymeric matrix.
- the multi-dosing, preservative removing devices may be stored without refrigeration for at least 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months before the drug is dispensed.
- ophthalmic formulation is dispensed using the multi-dosing, preservative removing device into an eye of a subject.
- the ophthalmic formulation that has passed through the polymeric matrix has substantially similar activity as before passing through the polymeric matrix. In some cases, the activity of the formulation that has passed through the polymeric matrix has substantially similar activity as the formulation on day 0 of storage, even after storage without refrigeration for at least 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months. In some cases, the activity comprises reducing the increased IOP in the eye of the subject.
- the ophthalmic formulation provided herein may be used for the treatment of a disorder or conditions associated with elevated intraocular pressure (IOP).
- IOP intraocular pressure
- Conditions and disorders associated with elevated IOP can include glaucoma and ocular hypertension.
- Glaucoma can comprise open-angle glaucoma, closed-angle glaucoma, congenital glaucoma, or secondary glaucoma.
- a solution, suspension, or emulsion administered to the eye may be administered topically, for example, with an eye drop.
- the compounds, or salts thereof, of the disclosure with low aqueous solubility may be formulated as aqueous suspensions.
- embodiments of the present invention provide ophthalmic agents that change the levels of intraocular pressure IOP in an eye.
- Levels of intraocular pressure in an individual may naturally fluctuate and change. For example, at nighttime in a reclining position is associated with higher IOP than during the day in a sitting position.
- a normal range of intraocular pressure is generally between 10 and 21 mmHg.
- IOP exceeding 21 mmHg is generally associated with problematic conditions.
- Conditions that cause elevated levels of IOP can include ocular hypertension, glaucoma, acute stress and/or anxiety. Glaucoma is a group of eye conditions that can damage the optic nerve.
- Glaucoma has four major types including: open-angle glaucoma, angle-closure glaucoma (or closed-angle glaucoma), congenital glaucoma, and secondary glaucoma. Elevated IOP can also be caused by or associated with excessive aqueous production or excessive aqueous humor, inadequate aqueous drainage, eye trauma, pseudoexfoliation syndrome, pigment dispersion syndrome, and corneal arcus. Moreover, individuals can be at greater risk for developing IOP depending on myriad factors. Nonlimiting factors can include age, family history of ocular hypertension or glaucoma, ethnicity, and systemic medication. Individuals having or suspected of having an increased IOP may utilize treatment that lower pressure in the eye as provided herein .
- ophthalmic formulations comprising an ophthalmic agent and a preservative.
- ophthalmic formulations comprise a complexing agent.
- formulations are also referred herein as solutions, suspensions, or emulsions.
- the solutions, suspensions, or emulsions comprise a complexing agent.
- a solution, suspension, or emulsion may be used in any of the methods described herein.
- the solution, suspension, or emulsion may additionally comprise one or more pharmaceutically acceptable excipients.
- Embodiments of the present disclosure may provide an ophthalmic agent for delivery to an eye.
- the ophthalmic agent may be a therapeutic agent for treating increased IOP.
- the solutions, suspensions, or emulsions comprise a preservative and an ophthalmic agent.
- the ophthalmic agent comprises a hydrophobic ophthalmic agent.
- the solution, suspension, or emulsion comprises a complexing agent.
- Ophthalmic agents may comprise compounds and salts, for use in the treatment of ophthalmic diseases.
- the solution, suspension, or emulsion may comprise one or more pharmaceutically acceptable excipients.
- the disclosed compounds and salts can be used, for example, forthe treatmentor prevention of vision disorders and/or for use during ophthalmological procedures forthe prevention and/or treatment of ophthalmic disorders.
- an ophthalmic agent may be used to lower intraocular pressure.
- an ophthalmic agent to lower intraocular pressure comprises a prostaglandin or prostaglandin analog, atopical P-adrenergic antagonist, a carbonic anhydrase inhibitor, a cholinergics, an a-adrenergic agonist, a parasympathomimetic miotic agent, or combinations thereof.
- Nonlimiting examples of ophthalmic agents provided to lower IOP can include but are not limited to: brimonidine tartrate, aceclidine, bimatoprost, levobunolol hydrochloride, brimonidine tartrate/timolol maleate, brinzolamide, betaxolol hydrochloride, pilocarpine hydrochloride, apraclonidine, brinzolamide/brimonidine tartrate, travoprost, timolol maleate, latanoprost, dorzolamide hydrochloride, tafluprost, latanoprostene bunod, netarsudil, apraclonidine, and dorzolamide/timolol.
- ophthalmic agents may be used in conjunction with a compressible bottle.
- Ophthalmic agents may comprise brandname drugs and formulations including, but not limited to, Alphagan, Lumigan, Betagan, Combigan, Azopt, Betoptic S, Isopto Carpine, lopidine, Simbrinza, Travatan Z, Isralol, Zalatan, Trusopt, Timoptic, Ziotan, Vesneo, Vyzulta, PRX-100, Cosopt, and other agents described herein.
- the ophthalmic agent comprises latanoprost.
- the ophthalmic agent comprisestimolol.
- the ophthalmic agent comprises brinzolamide.
- the ophthalmic agent comprises brimonidine. In some embodiments the ophthalmic agent comprises travoprost. In some embodiments the ophthalmic agent comprises bimatoprost. In some embodiments the ophthalmic agent comprises netarsudil. In some embodiments the ophthalmic agent comprises latanoprost bunod. In some embodiments the ophthalmic agent comprises dorzolamide. In some embodiments the ophthalmic agent comprises aceclidine.
- the ophthalmic agents may be dissolved in aqueous solution.
- the solution may be sterilized and buffered to appropriate pH.
- the solution may comprise inactive ingredients such as sodium chloride, sodium citrate, hydroxy ethyl cellulose, sodium phosphate, citric acid, sodium dihydrogen phosphate, polyoxyl 40 hydrogenated castor oil, tromethamine, boric acid, mannitol, glycerine edetate disodium, sodium hydroxide, and/or hydrochloric acid.
- the fluid comprises a preservative in addition to an ophthalmic agent.
- Example preservatives include but are not limited to: benzalkonium chloride (BAK), EDTA, quaternary ammonium compounds, stabilized oxychloro complexes (Purite®), solutions of borate, sorbitol, propylene glycol, and zinc (Sofzia®), etc.
- BAK benzalkonium chloride
- EDTA quaternary ammonium compounds
- Purite® stabilized oxychloro complexes
- solutions of borate borate
- sorbitol propylene glycol
- zinc Tinzia®
- Ophthalmic agents for the treatment of, for example, ocular hypertension, glaucoma, increased intraocular pressure may be administered to a patient as a solution, suspension, or emulsion delivered to an eye topically via a compressible bottle, a dropper bottle, or similar delivery mechanism.
- the solution, suspension, or emulsion may be subject to contamination such as microbial, fungal, or particulate contamination, which maybe adverse to patient health.
- a preservative may be added to the solution, suspension, or emulsion; however, patient exposure to preservatives may have adverse effects to eye health. It may be advantageous to limit patient exposure to preservative by providing a preservative removing device which may remove a preservative from the solution, suspension, or emulsion while maintaining the activity of the solution, suspension, or emulsion.
- the ophthalmic agent to be dispensed comprises an active ingredient selected from brimonidine tartrate, aceclidine, bimatoprost, levobunolol hydrochloride, brimonidine tartrate/timolol maleate, brinzolamide, betaxolol hydrochloride, pilocarpine hydrochloride, apraclonidine, brinzolamide/brimonidine tartrate, travoprost, timolol maleate, latanoprost, dorzolamide hydrochloride, tafluprost, latanoprostene bunod, netarsudil, apraclonidine, and dorzolamide/timolol.
- an active ingredient selected from brimonidine tartrate, aceclidine, bimatoprost, levobunolol hydrochloride, brimonidine tartrate/timolol maleate, brinzolamide, betaxolol hydrochloride, pi
- the ophthalmic agent to be dispensed comprises the active ingredient latanoprost. In some embodiments, the ophthalmic agent to be dispensed comprises the active ingredient timolol. In such embodiments, the ophthalmic agent may be an active ingredient in the treatment of elevated intraocular pressure, glaucoma, and/or ocular hypertension.
- ophthalmic agents described herein have various associated activity to treat one or more disease or disorder of the eye.
- the ophthalmic agent comprises a hydrophobic ophthalmic agent.
- the activity of an ophthalmic agent can comprise changing the levels of intraocular pressure (IOP) of an eye.
- the activity of the ophthalmic agent comprisestreating ocular hypertension or glaucoma, or a combination thereof.
- the activity of the ophthalmic agent comprises improving visual acuity.
- the activity of an ophthalmic agent reduces IOP, such as by reducing IOP to about23, about 22, about21, about20, about 19, about 18, about 17, or about 16 mmHg or lower.
- the activity of an ophthalmic agent can comprise reducing IOP to about 16 mmHg to about 23 mmHg.
- the activity of the ophthalmic agent reduces IOP, such as by reducing IOP by at least about 1, about 2, about 3, about 4, about 5, about 6, about?, about 8, about 9, or about 10 mmHg.
- the activity of an ophthalmic agent can comprise reducing IOP by at least about 1 mmHg to about 10 mmHg.
- IOP in a healthy individual can fluctuate over the course of a day.
- the normal baseline for IOP is between 10 and21 mmHg.
- the activity of the ophthalmic agent maintains IOP, such as by maintaining IOP below about 25, about 24, about 23, about 22, or about 21 mmHg.
- the activity of the ophthalmic agent maintains IOP below about 21 mmHg to below about 25 mmHg.
- a removal of a preservative does not substantially change the activity of the ophthalmic agent.
- a preservative-removing device delivers an ophthalmic agent maintaining an activity sub stantially similar to a preserved ophthalmic agent.
- a concentration of an ophthalmic agent in a solution, suspension, or emulsion of the present disclosure can be from about 0.01% (w/w) to about 1.5% (w/w), about 0.03% (w/w) to about 1.4% (w/w) about 0.05% (w/w) to about 1.3% (w/w), about 0.1% (w/w) to about 1.1 % (w/w), about 0.2% (w/w) to about 1.0 % (w/w), about 0.3% (w/w) to about 0.9% (w/w), about 0.4% (w/w) to about 0.8% (w/w), or about 0.5% (w/w) to about 0.7% (w/w).
- the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be between 0.01% (w/w) and 0.6% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be between 0.05% (w/w) and 0.3% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion canbe less than 0.05% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be about 0.25% (w/w) to about 0.5% (w/w).
- the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be about 0.15% (w/w) to about 0.2% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be from about 1 millimolar to about 1000 millimolar, about 100 millimolar to about 900 millimolar, about 200 millimolar to about 800 millimolar, about 300 millimolar to about 700 millimolar, about 400 millimolar to about 600 millimolar, about 100 millimolar, about 200 millimolar, about 300 millimolar, about 400 millimolar, about 500 millimolar, about 600 millimolar, about 700 millimolar, about 800 millimolar, about 900 millimolar, or about 1000 millimolar. In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion is less than about 1000 millimolar, about 750 millimolar, about 500 millimolar, about 250 millimolar, or about 100 millimolar
- the preservative removing device comprises a multi-dosing preservative-removal device.
- a preservative removal device can be used multiple times to deliver an uncontaminated, preservative-free ophthalmic agent to the eye of an individual.
- the preservative removal device can maintain the activity of the ophthalmic agent without refrigeration for a period of more than about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months or more.
- the preservative-removal device maintains the activity of the ophthalmic agent without refrigeration for about 1 month to about 6 months or more.
- the preservative removal device maintains the activity of the ophthalmic agent while maintaining the safety of the ophthalmic agent.
- the preservative removing device comprises a portable device.
- the portable device canbe held in a hand of an individual.
- Activity of an ophthalmic agent canbe measured with instrumentation and/or an individual’s ability to distinguish shapesand the details of objects at given distances with corrective lenses.
- Methods of measuring the activity of an ophthalmic agent can comprise measurement of fluid pressure in an eye such as by using applanation tonometry (e.g., Goldmann Applanation Tonometry), non-contact tonometry or air-puff tonometry (e.g., the ocular response analyzer), pneumotonometry (e.g., Langham ocular blood flow pneumotonometer), rebound tonometry (e.g., iCare One), dynamic contour tonometry (e.g., dynamic contour tonometer), applanation resonance tonometry (BioResonator ART), best- corrected visual acuity (BCVA), biomicroscopy (e.g., slit-lamp biomicroscopy), paychymetry, dilated ophthalmoscopy, perimetry, subject-rated drop comfort/tolerability,
- activity of an ophthalmic agent can be measured using applanation tonometry (e.g., Goldmann Applanation Tonometry). In some embodiments, activity of an ophthalmic agent can be measured using best-corrected visual acuity (BCVA). In some embodiments, activity of an ophthalmic agent can be measured using biomicroscopy (e.g., slit-lamp biomicroscopy). In some embodiments, activity of an ophthalmic agent can be measured using applanation tonometry (e.g., paychymetry, dilated ophthalmoscopy, perimetry, subject-rated drop comfort/tolerability, and/or blood samples). In some embodiments, activity of an ophthalmic agent can be measured using paychymetry.
- applanation tonometry e.g., Goldmann Applanation Tonometry
- activity of an ophthalmic agent can be measured using best-corrected visual acuity (BCVA).
- activity of an ophthalmic agent can be measured using biomicro
- activity of an ophthalmic agent can be measured using dilated ophthalmoscopy. In some embodiments, activity of an ophthalmic agent can be measured using perimetry. In some embodiments, activity of an ophthalmic agent can be measured using subject-rated drop comfort/tolerability. In some embodiments, activity of an ophthalmic agent can be measured using blood samples of a subject. Preservative
- the present disclosure provides formulations comprising one or more preservatives for solutions, suspensions, or emulsions of ophthalmic agents of the present disclosure.
- Preservatives may comprise compounds and salts, for use as preservatives for solutions, emulsions, or suspensions of ophthalmic agents.
- the one or more preservatives may for example prevent microbial and/or fungal growth causing harmful effects (e.g., permanent vision loss, death).
- the one or more preservatives may for example prevent physical or chemical deterioration of an ophthalmic agent.
- preservatives e.g., benzalkonium chloride (BAK)
- BAK benzalkonium chloride
- preservatives may keep products sterile, preventing microbial growth such as bacteria, fungus, and mold and reducing concerns of contamination.
- the use of preservatives may eliminate the need for special handling requirements which can reduce harmful environmental effects, enhance shelf life after opening, and cutback on the need to use unusual packaging.
- Use of preservatives may ensure the active ingredient concentration stays in solution.
- preservatives may eliminate or reduce the need for surfactants (e.g., cremophore), maintain drug concentration between doses, and eliminates the need for less favorable formulations (e.g., emulsion).
- preservatives administered to the eye of a subject can damage the ocular surface, increase inflammation, and reduce surgical success.
- preservative agents can include benzalkonium chloride, ethylenediaminetetraacetic acid(EDTA), quaternary ammonium compounds, stabilized oxychloro complexes (Purite®), solutions of borate, sorbitol, propylene glycol, and zinc (Sofzia®), etc.
- a formulation of the disclosure comprises the preservative of quaternary ammonium compounds.
- the preservative comprises benzalkonium chloride (BAK).
- BAK can be present in the solution, suspension, or emulsion of the ophthalmic agent at a concentration of about 0.01 mg/mL to about 0.5 mg/mL.
- the Purite® preservative system includes Stabilized Oxy chloro Complex (SOC), a combination of chlorine dioxide, chlorite, and chlorate. When exposed to light, SOC dissociates into water, oxygen, sodium, and chlorine free radicals which cause oxidation of intracellular lipids and glutathione, interrupting vital enzymes for cell function and maintenance.
- SOC Stabilized Oxy chloro Complex
- the particulate plug of the disclosure can include a material that has a high affinity for free radicals such as activated charcoal or antioxidants such as vitamin E.
- the SofZia® preservative system in TravatanZ contains borate, sorbitol, propylene glycol, and zinc. Without intending to be bound by theory, it is believed that the preservative effect is from a combination of borate and zinc.
- the particulate plug of the disclosure can include a metal chelating agent such as EDTA, anionic hydrogels that can extract cationic zinc through electrostatic interactions, cationic hydrogels or resins that can extract anionic borate ions through electrostatic interactions, or a neutralizing agent that can neutralize boric acid.
- removing a preservative from an ophthalmic medication may improve various signs and symptoms of OSD.
- signs of OSD include but are not limited to anterior/posterior blepharitis, eczema, hyperaemia, follicles, fluorescein staining, and superficial punctuate keratitis.
- symptoms of OSD include but are not limited to pain/discomfort during installation, foreign body sensations, stinging/burning sensations, dry eyes, tearing, and eyelid itching.
- solutions, suspensions, or emulsions of the present disclosure further comprise a complexing agent.
- the compound or salt of an ophthalmic agent of the disclosure exhibits high affinity for the matrix material and the addition of a complexing agent reduces the affinity of the ophthalmic agent for the matrix material.
- the solution, suspension, or emulsion comprises a cyclodextrin.
- the ophthalmic agent is hydrophobic.
- a polymeric matrix material designed to absorb a preservative such as benzalkonium chloride (BAK) may also absorb a hydrophobic ophthalmic agent.
- BAK benzalkonium chloride
- a complexing agent may decrease the affinity of the ophthalmic agent for the polymeric matrix. Utilizing a complexing agent, such as cyclodextrin, may change the relative hydrophobicity (hydrophilicity) of the ophthalmic agent relative to the polymer matrix material, thereby decreasing or reducing the affinity of the ophthalmic agent for the matrix.
- the complexing agent and the ophthalmic agent can form an inclusion compound.
- An inclusion compound is a complex in which one component (host) forms a cavity in which molecular entities of a second chemical species (guest) are located.
- the complexing agent is configured to host the ophthalmic agent.
- the cyclodextrin may be (2-hydroxypropyl)-P-cyclodextrin.
- the cyclodextrin may be (2-hydroxypropyl)-a-cyclodextrin, (2-hydroxypropyl)-y-cyclodextrin, a- cyclodextrin, P -cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y-cyclodextrin, or another substituted cyclic glucose polymer.
- the cyclodextrin is chosen from dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6- monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin or a combination thereof.
- the cyclodextrin is a randomly or selectively substituted at the hydroxyls with any chemistry and to any required degree for alpha, beta or gamma or any ring size cyclodextrin.
- other types of and degrees of substitution on the cyclodextrin rings are also known and possible. Any of these can used as complexing agents.
- CAVASOL® W7 HP PHARMA is pharmaceutical grade hydroxypropyl -beta-cyclodextrin from Wacker Chemie AG.
- CAVASOL® W7 HP PHARMA is a highly soluble beta-cyclodextrin derivative.
- the solution, suspension, or emulsion may comprise the cyclodextrin at a concentration of 127 pM (micromolar). In some embodiments, the solution, suspension, or emulsion may comprise the cyclodextrin at a concentration of greater than 1 pM, 2 pM, 5 pM, 10 pM, 20 pM, 50 pM, 100 pM, or more.
- the solution, suspension, or emulsion may comprise the cyclodextrin at a concentration of less than 500 pM, or it may be at a concentration of about 1 mM (millimolar), 2 mM, 5 mM, 10 mM, 20 mM, 50 mM, 100 mM, or less.
- the complexing agent may comprise a mixture of cyclodextrins comprising one or more cyclodextrins disclosed elsewhere herein. Excipients
- Devices and methods of the present disclosure may comprise formulating the solution, suspension, or emulsion with one or more inert, pharmaceutically -acceptable excipients.
- Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes or micelles comprising an ophthalmic agent as disclosed herein. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, tonicity agents and other pharmaceutically -acceptable additives.
- solutions, suspensions, or emulsions of the present disclosure further comprise one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the pharmaceutical agent into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- Pharmaceutically acceptable carriers include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or organic esters.
- aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or organic esters.
- the excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs.
- the composition can also be present in a solution suitable for topical administration, such as an eye drop.
- Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, hypromellose, Methocel, methyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and eth
- the solutions, suspensions, or emulsions of the disclosure may include one or more additional excipients.
- the amount of the excipient in a pharmaceutical formulation of the disclosure canbe about 0.01% to about 1000% by mass of the compoundin the solution, suspension, or emulsion.
- the amount of the excipient in a solution, suspension, or emulsion, of the disclosure canbe between 0.01% and 1000%, between 0.1% and 100%, between 1% and 50%, between 0.01% and 1%, between 10% and 100%, or between 500% and 1000% by mass of the compound in the solution, suspension, or emulsion.
- the amount of the excipient in a solution, suspension, or emulsion of the present disclosure can be about 0.01% and 1000%, between 0.1% and 100%, between l% and 50%, between 0.01% and 1%, between 10% and 100, or between 500% and 1000% by mass or by volume of the unit dosage form.
- the ratio of a compound of an ophthalmic agent of the present disclosure to an excipient in a pharmaceutical formulation of the present disclosure can be about 100 : about 1, about 50 : about20 : about 1, about 5 : about 1, about 1 : about 5, or about 1 : about 10.
- the ratio of a compound of an ophthalmic agent to an excipient in a solution, suspension, or emulsion of the present disclosure canbe within the range of between about 100 : about 1 and about 1 to about 10, between about 10 : about 1 and about 1 : about 1 , between about 5 : about 1 and about 2 : about 1 .
- a solution, suspension, or emulsion of the present disclosure comprises an agent for adjusting the pH of the formulation.
- the agent for adjusting the pH could be an acid, e.g., hydrochloric acid or boric acid, or a base, e.g., sodium hydroxide or potassium hydroxide.
- the agent for adjusting the pH is an acid such as boric acid.
- the formulation may comprise about 0.05 wt% to about 5 wt%, about 0.1% to about 4%, about 0.1% to about 3 wt%, about 0.1 wt% to about 2 wt%, or about 0.1 wt% to about 1 wt% of an agent for adjusting the pH.
- Solutions, suspensions, or emulsions of the disclosure can be formulated at any suitable pH.
- the pH of the solution, suspension, or emulsion comprises about 4, about4.5, about 5, about 5.5, about 6, about 6.5, about ?, about ?.5, about 8, about 8.5, or about 9 pH units.
- the pH of the solution, suspension, or emulsion is from about 4 to about 10, about 5 to about 9, about 6 to about 8, about 7 to about 8, about 7.2 to about 7.8, about 7.3 to about 7.5, or about 7.35 to about 7.45.
- the pH of the solution, suspension, or emulsion is about 7.4.
- the addition of an excipient to a pharmaceutical formulation of the present disclosure can increase or decrease the viscosity of the composition by at least 5%, at at least 25%, atleast 50%, atleast 75%, at least 90%, at least 95%, or atleast 99%. In some embodiments, the addition of an excipient to a pharmaceutical formulation of the present disclosure can increase or decrease the viscosity of the composition by no greater than 5%, no greaterthan 25%, no greaterthan 50%, no greater than 75%, nogreaterthan 90%, no greater than 95%, or no greater than 99%.
- an excipient that increases a viscosity may comprise polyvinyl alcohol, poloxamers, hyaluronic acid, carbomers, and polysaccharides, that is, cellulose derivatives, hydroxymethyl cellulose, hypromellose, Methacel, gellan gum, and xanthangum.
- an excipient that increases mucoadhesive properties may be added. Excipients that increase mucoadhesion may include polyacrylic acid, hyaluronic acid, sodium carboxymethyl cellulose, lectins, and chitosan.
- solutions, suspensions, or emulsions of the present disclosure further comprise an agent for adjusting the osmolarity of the solution, suspension, or emulsion, e.g., mannitol, sodium chloride, sodium sulfate, dextrose, potassium chloride, glycerin, propylene glycol, calcium chloride, and magnesium chloride.
- an agent for adjusting the osmolarity of the solution, suspension, or emulsion e.g., mannitol, sodium chloride, sodium sulfate, dextrose, potassium chloride, glycerin, propylene glycol, calcium chloride, and magnesium chloride.
- the solution, suspension, or emulsion comprises from about 0.1 wt% to about 10 wt%, about 1 wt% to about 5 wt%, about 1 wt% to about 4 wt%, or about 1 wt% to about 3 wt% of an agent for adjusting the osmolarity of the solution, suspension, or emulsion.
- the solution, suspension, or emulsion of the disclosure has an osmolarity from about 10 mOsmto about 1000 mOsm, about200 mOsm to about400mOsm, about250mOsm to about350 mOsm or about 290 mOsm to about 310m Osm.
- solutions, suspensions, or emulsions of the present disclosure further comprise a buffering agent, such as tromethamine, potassium phosphate, sodium phosphate, saline sodium citrate buffer (SSC), acetate, saline, physiological saline, phosphate buffer saline(PBS), 4-2-hydroxyethyl-l -piperazineethanesulfonic acid buffer (HEPES), 3-(N- morpholinojpropanesulfonic acid buffer (MOPS), and piperazine -N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), sodium acetate-boric acid stock solution, boric acid-sodium carbonate with sodium chloride solution, boric acid-sodium borate buffer, sodium and potassium phosphate buffers, boric acid-sodium carbonate with potassium chloride, or combinations thereof.
- a buffering agent such as tromethamine, potassium phosphate, sodium phosphate, saline sodium citrate
- the solution, suspension, or emulsion comprises from about 0.05 wt% to about 5 wt%, about 0.1 wt% to about 4 wt%, about 0.1 wt% to about 3 wt%, about 0.1 wt% to about 2 wt%, or about 0.1 wt% to about 1 wt% of an agent for buffering the solution, suspension, or emulsion.
- the solution emulsion or suspension provided herein comprises an alcohol as an excipient.
- alcohols include ethanol, propylene glycol, glycerol, polyethylene glycol, chlorobutanol, isopropanol, xylitol, sorbitol, maltitol, erythritol, threitol, arabitol, ribitol, mannitol, galactilol, fucitol, lactitol, and combinations thereof.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
- Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p -toluenesulfonic acid, salicylic acid, and the like.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
- the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
- the compounds may be synthesized using conventional techniques.
- these compounds are conveniently synthesized from readily available starting materials.
- Synthetic chemistry transformations and methodologies useful in synthesizing the compounds described herein are known in the art.
- the present disclosure provides salts of any one or both of an ophthalmic agent and a preservative.
- Pharmaceutically-acceptable salts include, for example, acid-addition salts and base-addition salts.
- the acid that is added to the compound to form an acid-addition salt can be an organic acid or an inorganic acid.
- a base that is added to the compound to form a base- addition salt can be an organic base or an inorganic base.
- a pharmaceutically-acceptable salt is a metal salt.
- Metal salts can arise from the addition of an inorganic base to a compound of the present disclosure.
- the inorganic base consists of a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate.
- the metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal.
- the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
- a metal salt is an ammonium salt, a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.
- Ammonium salts can arise from the addition of ammonia or an organic amine to a compound of the present disclosure.
- the organic amine is triethyl amine, diisopropyl amine, ethanol amine, diethanol amine, triethanol amine, morpholine, N- methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, pipyrazole, imidazole, pyrazine, or pipyrazine.
- an ammonium salt is a triethyl amine salt, a diisopropyl amine salt, an ethanol amine salt, a diethanol amine salt, a triethanol amine salt, a morpholine salt, an N-methylmorpholine salt, a piperidine salt, an N-methylpiperidine salt, an N-ethylpiperidine salt, a dibenzylamine salt, a piperazine salt, a pyridine salt, a pyrazole salt, an imidazole salt, or a pyrazine salt.
- Acid addition salts can arise from the addition of an acid to a compound of the present disclosure.
- the acid is organic.
- the acid is inorganic.
- the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p -toluenesulfonic acid, citric acid, oxalic acid, or maleic acid.
- the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt, a sulfite salt, a phosphate salt, isonicotinate salt, a lactate salt, a salicylate salt, a tartrate salt, an ascorbate salt, a gentisinate salt, a gluconate salt, a glucuronate salt, a saccharate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a methanesulfonate (mesylate) salt, an ethanesulfonate salt, a benzenesulfonate salt, a p -tol
- the methods and formulations described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs). Active metabolites of compounds or salts of any one of the compounds of the present disclosure having the same type of activity are included in the scope of the present disclosure.
- the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds and salts presented herein are also considered to be disclosed herein.
- an aqueous solutions, emulsions, or suspensions of the disclosure comprises at least 90 wt% water, such as at least 91 wt%, at least 92 wt%, at least 93 wt%, at least 94 wt%, at least 95 wt%, at least 96 wt%, at least 97 wt%, at least 98 wt%, or even at least 99 wt % of water.
- the present disclosure provides a preservative removal agent (e.g. a matrix).
- the preservative removal agent comprises a polymeric matrix.
- a preservative removal agent may rapidly and selectively remove preservatives of the present disclosure from a solution, suspension, or emulsion comprising an ophthalmic agent.
- the preservative removal agent may rapidly and selectively extract the preservative, allowing the eye drop formulation to flow through the plug with minimal pressure drop, yet with sufficient time to remove the preservative and with sufficient surface area and chemistry to adsorb the preservative.
- the matrix may comprise a material with a high affinity for the preservative, such as for example benzalkonium chloride (BAK), and at the same time a low affinity for a drug or other ophthalmological agent especially in some embodiments of this invention where the drug is also in the complex with a complexing or capping agent.
- the preservative removal agent may be sufficiently selective, such that at least 50 percent of the preservative may be removed and at least 50 percent of the drug may be retained by the solution.
- BAK benzalkonium chloride
- Non-limiting examples of a preservative removal agents may comprise solid, gel, and/or particulate matrices.
- the preservative removal agent may act as a physical barrier or filter. Additionally, or alternatively, the preservative removal agent may chemically remove a preservative such as by adsorption of the preservative onto the matrix.
- the preservative removal agent may be disposed in the outlet of a container, which container may contain the solution, suspension, or emulsion.
- a matrix disposed within a nozzle may be a porous polymeric matrix.
- the porous polymeric matrix may comprise a variety of materials. Such material may be safe and biocompatible. Such material may comprise but is not limited to, for example, Poly(2 -hydroxy ethyl methacrylate) (pHEMA), poly(hydroxylethyl methacrylate-co-methacrylic acid), crosslinked polyacrylamide, dimethyl acrylamide, methyl methacrylate, silicones, and/or any combination of the preceding materials.
- the matrix may be highly porous.
- the pore size in the matrix may be small enough so that the molecules, which may initially be far from the surface of the polymer in the matrix, may diffuse towards the polymer and adsorb.
- a matrix may have large interconnected pores which may allow flow of solution and adsorption of the preservative into the pores.
- the matrix may be formed as a porous gel, as a packed bed, and/or a structure formed by 3D printing soft lithography, electrospinning, or any other appropriate method.
- the matrix may comprise a microporous gel.
- the matrix may comprise a packed bed of pHEMA or crosslinked polyacrylamide or other polymeric particles. The particles may be macroporous.
- the particles may be spherical or non-spherical.
- the polymeric matrix may comprise nano or micron sized polymeric particles (e.g., nanogels or microgels).
- the polymeric matrix may comprise a cryogel.
- the polymeric matrix may be termed a hydrogel, be hydrophilic and absorb water readily.
- the particles themselves may directly impart the preservative effect, such as colloidal silver nanoparticles.
- particles of the formulations described herein have an average diameter from about 1 nm to about 10 pm, about 1 nm to about 10 pm, about 1 nm to about 5 pm, about 1 nm to about 2 pm, about 1 nm to about 1 pm, about 1 nm to about 900 nm, about 1 nm to about 800 nm, about 1 nm to about 700, about 1 nm to about 600 nm, about 1 nm to about 500 nm, about 1 nm to about 400 nm, about 1 nm to about 300 nm, about 1 nm to about 200 nm, or even from about 1 nm to about 100 nm.
- the average diameter is the average largest diameter or the average equivalent diameter.
- greater than 80% of the particles, such as greater than 90% or greater than 95% of the particles in the formulation have an average largest particle diameter of from about 1 nm to about 1000 pm, about 1 nm to about 10 pm, about 1 nm to about 5 pm, about 1 nm to about 2 pm, about 1 nm to about 1 pm, about 1 nm to about 900 nm, about 1 nm to about 800 nm, about 1 nm to about 700, about 1 nm to about 600 nm, about 1 nm to about 500 nm, about 1 nm to about 400 nm, about 1 nm to about 300 nm, about 1 nm to about 200 nm, or even from about 1 nm to about 100 nm.
- the average diameter is the average largest diameter or the average equivalent diameter.
- particles of the porous polymeric matrix described herein have an average diameter from about 100 nm to about 10 pm, about lOO nm to about 10 pm, about 100 nm to about 5 pm, about lOO nm to about 2 pm, about lOO nm to about 1 pm, about 100 nm to about 900 nm, about 100 nm to about 800 nm, about 100 nm to about 700, about 100 nm to about 600 nm, about 200 nmto about 500 nm, about 250 nm to about 600 nm, about 300 nm to about 600 nm, about 350 nmto about 700 nm, about 450 nm to about 550 nm, about 475 nm to about 525 nm, or from about 400 nm to about 700 nm.
- the average diameter is the average largest diameter or the average equivalent diameter.
- greater than 80% of the particles of the porous polymeric matrix, greater than 90% of the particles of the porous polymeric matrix, or greater than 95% of the particles of the porous polymeric matrix have an average diameter from about 100 nm to about 10 pm, about 100 nm to about 10 pm, about 100 nmto about 5 pm, about 100 nm to about 2 pm, about 100 nm to about 1 pm, about lOOnm to about 900 nm, about lOOnm to about 800 nm, about 100 nm to about 700, about 100 nm to about 600 nm, about 200 nm to about 500 nm, about 250 nm to about 600 nm, about 300 nm to about 600 nm, about 350 nm to about 700 nm, about 450 nm to about 550 nm, about 475 nm to about 525 nm, or from about 400 nm to about 700 nm.
- the average diameter is
- greater than 80% of the particles of the porous polymeric matrix, greater than 90% of the particles of the porous polymeric matrix, or greater than 95% of the particles in the formulation have an average diameter from about 10 pm to about 100 pm, about 50 pm to about 200 pm, about 90 pm to about 180 pm, about 150 pm to about 250 pm, about 200 pm to about 350 pm about 250 pm to about 500 pm , about 350 pm to about 800 pm, about 500 pm to about 1000 pm
- the average diameter is the average largest diameter or the average equivalent diameter.
- the particles may be irregular, regular, spherical, ovoid, or generally of any shape and the size can be defined as passing through a certain sized screen sieve.
- the matrix may comprise a tortuosity such that the flow path of a solution, suspension, or emulsion through the nozzle maybe significantly increased.
- the matrix is a packed bed of macroporous particles
- the packed beds of macroporous particles may have three levels of porosity: the spacebetween the particles, the macropores in the particles, and the inherent porosity of the polymer. In such an embodiment, all three levels of porosity may contribute to the tortuosity of the matrix.
- a matrix disposed within a nozzle may be a porous polymeric matrix. Applying a pressure behind the nozzle may cause fluid to flow through the nozzle via the flow path, along which path the preservative may be removed by adsorption onto the matrix.
- the polymer material, the hydraulic permeability, the partition coefficient, the adsorption rate, and the pore size in combination may aid in the absorption of all or most of the preservative from the solution and thus patient eye drops.
- the reduced preservative solution may subsequently be delivered directly to the eye.
- the porous polymeric matrix may rapidly and selectively extract the preservative, allowing the eye drop formulation to flow through the plug with minimal pressure drop, yet with sufficient time to remove the preservative and with sufficient surface area to adsorb the preservative.
- the matrix may comprise a material with a high affinity for the preservative, such as for example benzalkonium chloride (BAK), and low affinity for a drug or other ophthalmological agent.
- BAK benzalkonium chloride
- the porous polymeric matrix may comprise a high affinity for the preservative, such that at least 50 percent of the preservative may be removed and at least 50 percent of the drug may be retained by the solution.
- the porous polymeric matrix may comprise a variety of materials. Such material are safe and biocompatible.
- a polymer of the present disclosure may comprise various monomers, for example, Poly(2 -hydroxy ethyl methacrylate) (pHEMA) and/or and/or acrylamide (AM), dimethyl acrylamide (DMA) and/or methyl methacrylate (MMA) and/or N-Vinylpyrrolidone (NVP) and/or 2-acrylamido-2-methylpropane sulfonic acid (AMPS) and/or polyvinyl alcohol (PVA) and/or polymethylpropane sulfonic acid (PAMPS) and/or 2-sulfoethyl methacrylate (SEM) and/or acrylic acid (AA) and/or vinylphosphonic acid (VP) and/or t-butyl methacrylate (TBM) and/or Methacryloxypropyltris(trimethylsiloxy)silane (TRIS) and/or t
- the polymeric matrix may further comprise a cross linker.
- a crosslinker may comprise N,N’- methylenebis(acrylamide) (MB AM) and/or triacrylamido triazine (TATZ) and/or SR 351 and/or SR9035 and/or any combination of the preceding materials.
- the matrix material comprises a copolymer.
- a copolymer may comprise more than one species of monomer.
- Copolymers may be branched.
- Copolymers may be linear.
- Copolymers may comprise crosslinkers.
- Copolymers may be block copolymers, may be alternating copolymers, may be periodic copolymers, may be gradient copolymers may be statistical copolymers, may be stereoblock copolymers.
- the copolymers may exhibit phases of differing hydrophobicity or hydrophilicity. The hydrophobicity and/or hydrophilicity of the one or more monomers or cross-linkers may control the binding of a therapeutic agent or a preservative to the plug material.
- the polymeric matrix comprises polyvinyl alcohol crosslinked with citric acid or other suitable crosslinking agent to render it a hydrophilic hydrogel.
- the polymeric matrix can be crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid and copolymers such as poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide).
- Polymers of the present disclosure may generally follow an A/B/C formula where A and B are monomers, C is one or more cross-linkers, and A and B are not the same monomer.
- A may be an anionic hydrophilic monomer.
- monomers of type A may comprise AM or NVP.
- B may be an ionic hydrophilic monomer.
- monomers of typeB may comprise MAA, AMPS, SEM, AA, or VP.
- C may be a crosslinker.
- monomers of type C may comprise one or more of MB AM, TATZ, or SR 351.
- Polymers of the present disclosure may generally follow an A/C formula where A is a monomer as described above and C is one or more cross-linkers as described above.
- Polymers of the present disclosure may generally follow an B/C formula where B is a monomer as described above and C is one or more cross-linkers as described above.
- Polymers of the present disclosure may also comprise grafted copolymers such that components such as monomer A and with a cross-linker C are first copolymerized to form a crosslinked copolymer that can be isolated as a small bead or other shaped particle.
- the beads comprise spherical beads. These beads or particles can then be reswollen in water and a monomer of B type can added and then polymerized into or onto the bead or particle through the use a free radical “grafting” polymerization.
- the particles are made up of A/C copolymer with a “grafted” B polymer as part of the copolymer structure.
- Polymers of the present disclosure may comprise: AMPS/MBAM/TATZ 7.5/82.5/10, AMPS/MBAM/TATZ 7.5/77.5/15 AMPS/MBAM 7.5/92.5, BioRadBeads /AMPS 1 g/0.5, AMPS/MBAM 7.5/92.5, AMPS/MBAM/TATZ 7.5/87.5/5.0 (D-322-006-AW), SEM/MBAM 7.5/92.5, AM/2-Sulfoethyl MA(SEM)/MBAM 30/10/60, AMPS/MBAM 7.5/92.5; AMPS/MBAM 7.5/92.5, AMPS/MBAM 7.5/92.5, AMPS/MBAM 7.5/92.5, AMPS/MBAM 7.5/92.5, PVA/PAMPS/C A 4.8/1 .2/2.4 IPN, AMPS/MBAM/C A 4.8/1 .2/2.4 IPN, AMPS/MBAM/C A 4.8/1 .2/2.4 I
- any matrix material and any drug in association with a complexing agent may be used such that the drug/complex partition coefficient into the matrix may be lower by at least an order of magnitude or 2 orders of magnitude than the matrix’s affinity for the preservative.
- pHEMA, or S03- or P03H- or COO- groups on the polymer (or matrix) may bind BAK with a partition coefficient of about 100-500, or in some embodiments, 1000 depending on the BAK concentration and the structure of the matrix and the % content of those groups.
- the matrix may comprise a partition coefficient for the preservative from the solution, suspension, or emulsion of, for example, at least 10, at least 100, at least 1000, at least 10,000, or within a range defined by any two of the preceding values.
- the adsorption rate constant may be sufficiently high so that the time for adsorption of a drug molecule to the polymer may be less than the time to form a drop.
- the time to form a drop may comprise a time within a range from 0.1 to 10 seconds.
- the matrix may display a high hydraulic permeability such that relatively little pressure may be required to dispense a fluid.
- the hydraulic permeability may depend on the design of the filter. Larger pores in the matrix may allow for higher flow for a given pressure drop.
- hydraulic permeability may be larger than about 0.01 Darcy (Da).
- a nozzle may comprise a permeability of about 0.1 Darcy.
- a hydraulic permeability of 1 to 10 Darcy may allow fluid to be retained in the filter during instances when the pressure may be lowered sub sequent to formation of a drop.
- a larger hydraulic permeability may allow the same plug to work for a wide range of formulations including, for example, high viscosity formulations, such as rewetting eye drops.
- the porous polymeric matrix comprises a hydraulic permeability of, for example, 0.01 Da, 0.1 Da, 1 Da, 10 Da, 100 Da, 1000 Da or a hydraulic permeability within a range defined by any two of the preceding values.
- the matrix may be highly porous.
- the pore size in the matrix may be small enough so that the molecules, which may initially be far from the surface of the polymer in the matrix, may diffuse towards the polymer and adsorb.
- a matrix may comprise large interconnected pores which may allow flow of solution and adsorption of the preservative into the pores.
- the matrix may be formed as a porous gel, as a packed bed, and/or a structure formed by 3D printing soft lithography, electrospinning of a fiber, or any other appropriate method.
- the matrix may comprise a microporous gel.
- the matrix may comprise a packed bed of pHEMA or crosslinked polyacrylamide with an anionic moiety or functionality as part of the polymer or other polymeric particles.
- the particles may be macroporous.
- the particles may be spherical or non-spherical.
- the polymeric matrix may comprise nano or micron sized or 10s of microns or 100s of microns of polymeric particles (e.g., nanogels or microgels).
- the polymeric matrix may comprise a cryogel.
- the particles themselves may directly impart the preservative effect, such as colloidal silver nanoparticles.
- the particles may need to be stably held in the nozzle and prevented from eluting from the nozzle.
- the particles may be attached to the container walls through long polymeric chains and/or by placing a filter at the exit from the device. Additionally, or alternatively, the walls of the container or other surfaces may comprise preservative attached thereupon and/or incorporated therein.
- the preservative source comprises a pHEMA membrane with 1 -10% by volume equilibrated with BAK.
- the matrix comprises pre-loaded with BAK at a concentration to inhibit microbial growth over time.
- the porous matrix material may comprise a tortuosity such that the flow path of a solution, suspension, or emulsion through the nozzle increases.
- the packed beds of macroporous particles may comprise three levels of porosity: the space between the particles, the macropores in the particles, and the inherent porosity of the polymer. In such embodiments, all three levels of porosity may contribute to the tortuosity of the matrix.
- the tortuosity of the porous material combined with the geometry nozzle itself may increase the flow path in accordance with a multiplicative factor of a first flow path length corresponding to flow defined by the nozzle geometry and a second flow path length corresponding to the tortuosity of the porous material.
- the pressure needed for drop creation may exceed the Young Laplace pressure during drop creation, which may be about 2o/R. d where c is the surface tension and Rd is the radius of the drop. Estimating R d ⁇ 0.5 mm based on a drop volume of 30 pL, and using the surface tension of water may yield a Young Laplace pressure of about lOOPa.
- the pressure to form a drop may additionally exceed the pressure needed to displace 30 pL of volume.
- Typical drop volumes may comprise a volume within a range between 1 pL and 100 pL.
- the minimum pressure to form a drop may be ⁇ 0.01 Atm (1000 Pa) based on an ideal gas estimate using a 3mLbottle at atmospheric pressure, but may be lower for larger bottles at varying pressures. Maximum pressure to form a drop may be limited by a patient strength. The pressure to form a drop may be within a range between 0.01 Atm and 0.5 Atm.
- the rate of liquid flow through the plug may depend on the applied pressure as well as the design parameters of the matrix including, but not limited to, length, area, porosity, hydraulic permeability, flow path length, etc. These design parameters may be considered individually or in combination to remove preservative without excessive squeeze pressure.
- the rate of liquid flow may affect the time to form a drop.
- a solution, suspension, or emulsion can comprise an ophthalmic agent and a preservative.
- a polymeric matrix is configured such that the preservative maybe selectively removedin the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix may be configured such that about 1% to about 99%, about 20% to about 80%, about 40% to about 60%, about 10%, about 20%, about 30%, about40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the preservative is selectively removedin the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than about 50%, 40%, 30%, 20%, 10%, or 5% of the preservative.
- the ophthalmic agent comprises a hydrophobic ophthalmic agent.
- the preservative comprises benzalkonium chloride (BAK).
- ophthalmic agents have an associated activity (e.g., lowering intraocular pressure (IOP)).
- a solution, suspension, or emulsion can comprise an ophthalmic agent and a preservative.
- a polymeric matrix is configured such that an activity of the ophthalmic agent is substantially maintained in the solution, suspension, or emulsion after passing through the polymeric matrix.
- the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least about 30% to about 95%, about 40% to about 80%, about 50% to about 70%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95% of an activity of the ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- a polymeric matrix can comprise an active matrix component and an inactive matrix component.
- the inactive matrix component can have substantially no affinity for the ophthalmic agent or the preservative.
- the active polymeric matrix component comprises polymeric hydrogel.
- the inactive polymeric matrix component is a polyolefin.
- inactive polymeric matrix component can comprise a polyethylene, polypropylene, or copolymers thereof.
- the inactive polymeric matrix component can comprise a low-density polyethylene (LDPE).
- LDPE low-density polyethylene
- a solution, suspension, or emulsion can be disposed within a chamber of a compressible bottle.
- a compressible bottle can comprise an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding the solution, suspension, or emulsion.
- the solution, suspension, or emulsion comprises an ophthalmic agent.
- the solution, suspension, or emulsion may further comprise a preservative.
- applying pressure to the compressible bottle passes the solution, suspension, or emulsion through the polymeric matrix to the outlet.
- applying pressure to the compressible bottle forms a drop at the outlet.
- the drop comprises the solution, suspension, or emulsion.
- the compressible bottle comprises a multi -dosing device.
- compressible bottle comprises a portable device.
- the compressible bottle can be held in a hand of an individual.
- the compressible bottle comprises a mass of less than about 100 grams, about 90 grams, about 80 grams, about 70 grams, about 60 grams, about 50 grams, about 40 grams, about 30 grams, about 20 grams, about 10 grams, or about 5 grams.
- the mass of the compressible bottle can be between about 2 grams and about 100 grams.
- the dosage and frequency (single or multiple doses) administered to a mammal may vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health -related problems.
- Other therapeutic regimens or agents may be used in conjunction with the methods and compounds of this disclosure. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
- Dosages may be varied depending upon the requirements of the patient and the compound being employed.
- the dose administered to a patient should be sufficient to affect a beneficial therapeutic response in the patient over time.
- the size of the dose also may be determined by the existence, nature, and extent of any adverse side effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
- Dosage amounts and intervals may be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This may provide a therapeutic regimen that is commensurate with the severity of the individual's disease state
- the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on howthe value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1 , 2, 3, or 4 standard deviations. In certain embodiments, the term “about” or “approximately” means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.
- the term "about” or “approximately” means within 40.0 mm, 30.0 mm, 20.0 mm, 10.0mm 5.0 mm 1 .0 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm or 0. 1 mm of a given value or range.
- OD refers to right eye of a subject.
- OS refers to left eye of a subject.
- the terms “user”, “subject” or “patient” are used interchangeably.
- the terms “subject” and “subjects” refers to an animal (e.g., birds, reptiles, and mammals), a mammal including a primate (e.g., a monkey, chimpanzee, and a human) and a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, cat, dog, rat, and mouse).
- a primate e.g., a monkey, chimpanzee, and a human
- a non-primate e.g., a camel, donkey, zebra, cow, pig, horse, cat, dog, rat, and mouse.
- the mammal is 0 to 6 months old, 6 to 12 months old, 1 to 5 years old, 5 to 10 years old, 10 to 15 years old, 15 to 20 years old, 20 to 25 years old, 25 to 30 years old, 30 to 35 years old, 35 to 40 years old, 40 to 45 years old, 45 to 50 years old, 50 to 55 years old, 55 to 60 years old, 60 to 65 years old, 65 to 70 years old, 70 to 75 years old, 75 to 80 years old, 80 to 85 years old, 85 to 90 years old, 90 to 95 years old or 95 to 100.
- the subject or patient is a pig.
- the pig is 0 to 6 months old, 6 to 12 months old, 1 to 5 years old, 5 to 10 years old or 10 to 15 years old.
- the natural lifespan of a pig is 10-15 years.
- the terms “treating” or “treatment” refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being.
- the treatment or amelioration of symptoms may be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
- the term "treating" and conjugations thereof, include prevention of an injury, pathology, condition, or disease.
- the term “prevent” or “preventing” as related to a disease or disorder may refer to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
- an “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition).
- An example of a “therapeutically effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.”
- a “reduction of’ a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- the term “activity” when describing an ophthalmic agent herein refers to treatment provided by an ophthalmic agent (e.g., lowering intraocular pressure (IOP) of an eye) to a symptom or a sign of a disorder or a condition.
- the treatment comprises reducing the symptom or a sign of a disorder or a condition in a subj ect having the disorder or the condition.
- safety when describing an ophthalmic agent, an ophthalmic formulation, or a solution, suspension, or emulsion herein refers to a characteristic that protects against harmful contamination (e.g., fungal or bacterial contamination).
- substituted refers to moieties having substituents replacing a hydrogen on one or more carbons or heteroatoms of the structure. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom andthe substituent, andthatthe substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds.
- the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
- the permissible substituents can be one or more and the same or different for appropriate organic compounds.
- the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
- Embodiment 1 A method for providing a hydrophobic ophthalmic agent comprising: providing a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and providing a polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- Embodiment 2 A method for providing a hydrophobic ophthalmic agent comprising: providing a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and providing a polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- a method for providing an ophthalmic agent comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- Embodiment 3 A method for delivering a hydrophobic ophthalmic agent to an eye of a subject to reduce intraocular pressure comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- Embodiment 4 The method of any one of preceding embodiments, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- Embodiment 5 The method of any one of preceding embodiments, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- Embodiment 6 The method of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
- IOP intraocular pressure
- Embodiment 7 The method of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof.
- Embodiment 8 The method of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises improving visual acuity.
- Embodiment 9 The method of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg.
- Embodiment 10 The method of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower.
- Embodiment 11 The method of any one of the preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- IOP intraocular pressure
- Embodiment 12 The method of any one of preceding embodiments, wherein the reduction in the intraocular pressure is measured by applanation tonometry.
- Embodiment 13 The method of any one of preceding embodiments, wherein the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- Embodiment 14 The method of any one of the preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or21 mmHg.
- IOP intraocular pressure
- Embodiment 15 The method of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprostbunod, dorzolamide, or aceclidine, ora combination thereof.
- Embodiment 16 The method of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
- Embodiment 17 The method of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
- Embodiment 18 The method of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w).
- Embodiment 19 The method of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w).
- Embodiment 20 The method of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w).
- Embodiment 21 The method of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w).
- Embodiment 22 The method of any one of preceding embodiments, wherein the preservative is benzalkonium chloride.
- Embodiment 23 The method of any one of preceding embodiments, where a concentration of the preservative is less than 0.05% (w/w).
- Embodiment 24 The method of any one of preceding embodiments, wherein the polymeric matrix is a polymeric hydrogel.
- Embodiment 25 The method of any one of preceding embodiments, wherein the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co- acrylamide), or a combination thereof.
- Embodiment 26 The method of any one of preceding embodiments, wherein the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 - acrylamido-2-methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MAA methyl methacrylate
- AMPS 2 - acrylamido-2-methylpropane sulfonic acid
- SEM 2 -sulfoethyl methacrylate
- acrylic acid AA
- VP vinylphosphonic acid
- Embodiment 27 The method of any one of preceding embodiments, wherein the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- Embodiment 28 The method of embodiment 27, wherein the crosslinked polyacrylamide material is isolated in the form of spherical beads.
- Embodiment 29 The method of embodiment 27 or embodiment 28, wherein the at least one modifying monomer comprises 2-acrylamido-2 -methylpropane sulfonic acid (AMPS) or 2- sulfoethyl methacrylate (SEM).
- AMPS 2-acrylamido-2 -methylpropane sulfonic acid
- SEM 2- sulfoethyl methacrylate
- Embodiment 30 The method of any one of preceding embodiments, wherein the solution, suspension, or emulsion further comprises a complexing agent.
- Embodiments 1 The method of embodiment 30, wherein the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
- Embodiment32 The method of embodiment 30, wherein the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix.
- Embodiment 33 The method of embodiment 30, wherein the complexing agent comprises a cyclodextrin.
- Embodiment34 The method of embodiment 33, wherein the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin.
- Embodiment35 The method of embodiment 33, wherein the cyclodextrin is atleastone of (2-Hydroxypropyl)-a-cyclodextrin, (2-Hydroxypropyl)-P-cyclodextrin, (2 -Hydroxyprop yl)-y- cyclodextrin, a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P- cyclodextrin, methyl-y-cyclodextrin, dimethyl -beta-cyclodextrin, highly sulphated-beta- cyclodextrin, 6-monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin, or
- Embodiment 36 The method of embodiment 30, wherein a concentration of the complexing agent is less than 200 micromolar.
- Embodiment 37 The method of any one of preceding embodiments, wherein the polymeric matrix comprises an active matrix component and an inactive matrix component.
- Embodiment38 The method of embodiment 37, wherein the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
- Embodiment 39 The method of embodiment 37 or embodiment 38, wherein the active polymeric matrix component is a polymeric hydrogel.
- Embodiment 40 The method of embodiments? or embodiment 38, wherein the inactive polymeric matrix component is a polyolefin.
- Embodiment 41 The method of embodiment 40, wherein the polyolefin is a polyethylene, polypropylene or copolymers thereof.
- Embodiment 42 The method of embodiment 41, wherein the polyolefin is a low-density polyethylene (LDPE).
- LDPE low-density polyethylene
- Embodiment 43 A multi-dosing delivery device for dispensing a hydrophobic ophthalmic agent, the device comprising: a bottle having an extended outlet; a polymeric matrix dispensed within the extended outlet; and a reservoir configured to hold a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative, wherein the polymeric matrix is configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
- Embodiment 44 The device of embodiment 43, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- Embodiment 45 The device of embodiment 43 or embodiment 44, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- Embodiment 46 The device of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
- IOP intraocular pressure
- Embodiment 47 The device of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof.
- Embodiment 48 The device of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises improving visual acuity.
- Embodiment 49 The device of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mm Hg.
- Embodiment 50 The device of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower.
- Embodiment 51 The device of any one of the preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
- IOP intraocular pressure
- Embodiment 52 The device of any one of preceding embodiments, wherein the reduction in the intraocular pressure is measured by applanation tonometry.
- Embodiment 53 The device of any one of preceding embodiments, wherein the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
- Embodiment 54 The device of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
- the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
- Embodiment 55 The device of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
- Embodiment 56 The device of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
- Embodiment 57 The device of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w).
- Embodiment 58 The device of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w).
- Embodiment 59 The device of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w).
- Embodiment 60 The device of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w).
- Embodiment 61 The device of any one of preceding embodiments, wherein the preservative is benzalkonium chloride.
- Embodiment 62 The device of any one of preceding embodiments, where a concentration of the preservative is less than 0.05% (w/w).
- Embodiment 63 The device of any one of preceding embodiments, wherein the polymeric matrix is a polymeric hydrogel.
- Embodiment 64 The device of any one of preceding embodiments, wherein the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co- acrylamide), or a combination thereof.
- Embodiment 65 The device of any one of preceding embodiments, wherein the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 - acrylamido-2-methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- MAA methyl methacrylate
- AMPS 2 - acrylamido-2-methylpropane sulfonic acid
- SEM 2 -sulfoethyl methacrylate
- acrylic acid AA
- VP vinylphosphonic acid
- Embodiment 66 The device of any one of preceding embodiments, wherein the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
- Embodiment 67 The device of embodiment 66, wherein the crosslinked polyacrylamide material is isolated in the form of spherical beads.
- Embodiment68 The device of embodiment66 or embodiment 67, wherein the atleast one modifying monomer comprises 2-acrylamido-2 -methylpropane sulfonic acid (AMPS) or 2- sulfoethyl methacrylate (SEM).
- AMPS 2-acrylamido-2 -methylpropane sulfonic acid
- SEM 2- sulfoethyl methacrylate
- Embodiment 69 The device of any one of preceding embodiments, wherein the solution, suspension, or emulsion further comprises a complexing agent.
- Embodiment 70 The device of embodiment 69, wherein the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
- Embodiment 71 The device of embodiment 69, wherein the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix.
- Embodiment 72 The device of embodiment 69, wherein the complexing agent comprises a cyclodextrin.
- Embodiment 73 The device of embodiment 72, wherein the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin.
- Embodiment 74 Embodiment 74.
- cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2-Hydroxypropyl)-P-cyclodextrin, (2 -Hydroxyprop yl)-y- cyclodextrin, a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P- cyclodextrin, methyl-y-cyclodextrin, dimethyl -beta-cyclodextrin, highly sulphated-beta- cyclodextrin, 6-monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin.
- Embodiment 75 The device of embodiment 69, wherein a concentration of the complexing agent is less than 200 micromolar.
- Embodiment 76 The device of any one of preceding embodiments, wherein the polymeric matrix comprises an active matrix component and an inactive matrix component.
- Embodiment 77 The device of embodiment 76, wherein the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
- Embodiment 78 The device of embodiment 76 or embodiment 77, wherein the active polymeric matrix component is a polymeric hydrogel.
- Embodiment 79 The device of embodiment 76 or embodiment 77, wherein the inactive polymeric matrix component is a polyolefin.
- Embodiment 80 The device of embodiment 79, wherein the polyolefin is a polyethylene, polypropylene or copolymers thereof.
- Embodiment 81 The device of embodiment 80, wherein the polyolefin is a low-density polyethylene (LDPE).
- LDPE low-density polyethylene
- TC-002 a non - limiting example embodiment of a solution, suspension, or emulsion described herein, TC-002, in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- OAG open-angle glaucoma
- OHT ocular hypertension
- TC-002 is 0.005% latanoprost ophthalmic solution preserved in a bottle with benzalkonium chloride, (BAK) where the bottle is configured to prevent BAK from being delivered to the subject.
- BAK benzalkonium chloride
- the objective of the study was to demonstrate substantial equivalence of latanoprost ophthalmic solution 0.005% (TC-002) compared to commercially available latanoprost ophthalmic solution 0.005% (LAT) in reducing intraocular pressure (IOP) in participants with glaucoma or ocular hypertension.
- the secondary objectives of the study were to assess the safety and tolerability of TC-002.
- POAG bilateral primary open -angle glaucoma
- IOP intraocular pressure
- PGA prostaglandin or analog
- IOP and diurnal IOP measured by Goldmann Applanation Tonometry
- BCVA best corrected visual acuity
- biomicroscopy dilated ophthalmoscopy
- pachymetry perimetry
- subject-rated drop comfort/tolerability investigational product levels (in the pharmacokinetic cohort)
- AE adverse effects
- Diurnal IOP was calculated as the average of 8 :00 AM, 10:00 AM, and 4:00 PM measurements at Weeks 2, 6, and 12.
- Ocular Surface Disease Index (OSD I) were recorded. This questionnaire consisted of 5 questions pertaining: (1) light sensitivity, (2) gritty feeling, (3) pain or soreness, (4) blurred vision, and (5) poor vision. Subjects also recorded their drop administration in a dosing diary to monitor treatment compliance.
- IOP Intraocular pressure
- Ttc lowered IOP by about 1 mmHg more than commercially available, preserved timolol.
- Both Ttc and commercially available, preserved latanoprost maintained IOP under about 20 mmHg over the study period.
- Ttc maintained IOP under 19.5 mmHg overthe study period.
- a graph summarizing the data is found in FIG. 3B.
- TC-002 Compared to commercially available, BAK preserved latanoprost ophthalmic solution 0.005% in reducing ocular pressure (IOP) in subjects.
- TC-002 is 0.005% latanoprost ophthalmic solution preserved in a bottle with benzalkonium chloride, (BAK) where the bottle is configured to prevent BAK from being delivered to the subject.
- BAK benzalkonium chloride
- the mean baseline IOP measurement for the TC-002 group was 18.1 mmHG(OD) and 18.0 (OS).
- the mean baseline IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 17.0 (OD) and 15.8 mmHg (OS).
- the mean day 8 IOP measurement for the TC-002 group was 17.8 mmHg (OD), a decrease of 0.3 mmHg from the baseline measurement and 18.2 mmHg (OS), an increase of .2 mmHg from the baseline measurement.
- the mean day 8 IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 16.4 mmHg (OD), a decrease of 0.6 mmHg from the baseline measurement and 17.2 mmHg (OS), an increase of 1 .4 mmHg from the baseline measurement.
- the mean day 15 IOP measurement for the TC-002 group was 18.7 mmHg (OD), an increase of 0.6 mmHg from the baseline measurement and 19.5 mmHg (OS), an increase of 1.5 mmHg from the baseline measurement.
- the mean day 15 IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 18 mmHg (OD), an increase of 1 .0 mmHg from the baseline measurement and 16.8 mmHg (OS), an increase of 1.0 mmHg from the baseline measurement.
- the mean day 27 IOP measurement for the TC-002 group was 16.6 mmHg (OD), a decrease of 1.5 mmHg from the baseline measurement and 17.0 mmHg (OS), an decrease of 1.0 mmHg from the baseline measurement.
- the mean day 27 IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 18 mmHg (OD), an increase of 1.0 mmHg from the baseline measurement and 17.4 mmHg (OS), an increase of 1.6 mmHg from the baseline measurement. Over the nearly four week period, both groups demonstrated maintained reduced IOP close to the baseline. As discussed herein, the normal range of IOP is between 10 and 1 mmHg, met by all groups for each measurement. Furthermore, the maintenance in IOP between the commercially available, BAK preserved latanoprost ophthalmic solution group and the TC-002 group indicated substantial equivalence between the ophthalmic solutions. The data and a graph summarizing the data can be found in FIGS. 4B-4D.
- An example method of demonstrating the substantial of the activity of commercially available preserved timolol to a solution, suspension, or emulsion comprising the ophthalmic agent timolol and a preservative comprising benzalkonium chloride wherein the activity is reducing intraocular pressure (IOP) in subjects may be achieved by measuring the reduction of IOP in a subject administered commercially available, preserved timolol solution.
Abstract
Provided herein are devices and methods for removing a preservative from a solution, suspension, or emulsion comprising an ophthalmic agent, which substantially maintains one or more activity of the ophthalmic agent after passing through a polymeric matrix in the device.
Description
OPHTHALMIC AGENT IN PRESERVATIVE REMOVAL DEVICE
CROSS-REFERENCE
[0001] This application claims the benefit of U. S. Provisional Application No. 63/331, 142 filed April 14, 2022, and U.S. Provisional ApplicationNo. 63/449,538 filed March 2, 2023, which are incorporated by reference in their entirety.
BACKGROUND
[0002] Many ophthalmic solutions, suspensions, and emulsions for reducing intraocular pressure (IOP) in an eye comprise an ophthalmic agent and one or more preservatives to protect against contamination and to allow for long-term storage and use without refrigeration. However, the preservatives in the solution, suspension, and emulsion may cause corneal toxicity, ocular surface disease, irritation, or other unwanted side effects in the affected eye when administered to the affected eye. Thus, there is a need for systems and devices for delivering ophthalmic solution, suspension, and emulsion with little to no preservatives while the activity of the ophthalmic agent is maintained even after storage without refrigeration for long durations.
SUMMARY
[0003] Provided herein are methods and devices for dispensing an ophthalmic formulation comprising an ophthalmic agent and a preservative that removes the preservative as the ophthalmic formulation is dispensed while retaining an activity of an ophthalmic agent in the dispensed formulation. As the preservative stays in the formulation until the formulation is dispensed through a polymeric matrix, the formulation as dispensed as described herein can maintain the sterility, reduce the risk for ocular infection, allow for a multi-dose use delivery format that can be stored at room temperature or without a need for refrigeration, while reducing unwanted side effects and maintaining the activity of the ophthalmic agent once delivered to the eye.
[0004] In one aspect, provided is a method for providing a hydrophobic ophthalmic agent comprising: providing a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and providing a polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as
compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg. In some embodiments, the reduction in the intraocular pressure is measured by applanation tonometry. In some embodiments, the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof. In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar. In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w). In some embodiments, the polymeric matrix is a polymeric hydrogel. In some embodiments, the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a
combination thereof. In some embodiments, the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 -acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the crosslinked polyacrylamide material is isolated in the form of spherical beads. In some embodiments, the at least one modifying monomer comprises 2- acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM). In some embodiments, the solution, suspension, or emulsion further comprises a complexing agent. In some embodiments, the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound. In some embodiments, the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agentforthe polymeric matrix. In some embodiments, the complexing agent comprises a cyclodextrin. In some embodiments, the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interiorof the cyclodextrin. In some embodiments, the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin. In some embodiments, a concentration of the complexing agent is less than 200 micromolar. In some embodiments, the polymeric matrix comprises an active matrix component and an inactive matrix component. In some embodiments, the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative. In some embodiments, the active polymeric matrix component is a polymeric hydrogel. In some embodiments, the inactive polymeric matrix component is a polyolefin. In some embodiments, the polyolefin is a polyethylene, polypropylene or copolymers thereof. In some embodiments, the polyolefin is a low-density polyethylene (LDPE).
[0005] In one aspect, provided is a method for providing an ophthalmic agent comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removedin the solution, suspension, or emulsion after passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less th an 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg. In some embodiments, the reduction in the intraocular pressure is measured by applanation tonometry. In some embodiments, the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof. In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar. In some embodiments, a concentration of the hydrophobic ophthalmic agent is
between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration ofthe hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w). In some embodiments, the polymeric matrix is a polymeric hydrogel. In some embodiments, the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof. In some embodiments, the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the crosslinked polyacrylamide material is isolated in the form of spherical beads. In some embodiments, the at least one modifying monomer comprises 2- acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM). In some embodiments, the solution, suspension, or emulsion further comprises a complexing agent. In some embodiments, the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound. In some embodiments, the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix. In some embodiments, the complexing agent comprises a cyclodextrin. In some embodiments, the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interiorof the cyclodextrin. In some embodiments, the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6-
N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin. In some embodiments, a concentration of the complexing agent is less than 200 micromolar. In some embodiments, the polymeric matrix comprises an active matrix component and an inactive matrix component. In some embodiments, the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative. In some embodiments, the active polymeric matrix component is a polymeric hydrogel. In some embodiments, the inactive polymeric matrix component is a polyolefin. In some embodiments, the polyolefin is a polyethylene, polypropylene or copolymers thereof. In some embodiments, the polyolefin is a low-density polyethylene (LDPE).
[0006] In one aspect, provided is a method for delivering a hydrophobic ophthalmic agent to an eye of a subject to reduce intraocular pressure comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg. In some embodiments, the reduction in the intraocular pressure is measured by applanation tonometry. In some embodiments, the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within
2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof. In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar. In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agentis between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w). In some embodiments, the polymeric matrix is a polymeric hydrogel. In some embodiments, the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof. In some embodiments, the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 - acrylamido-2-methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the crosslinked polyacrylamide material is isolated in the form of spherical beads. In some embodiments, the at least one modifying monomer comprises 2-acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM). In some embodiments, the solution,
suspension, or emulsion further comprises a complexing agent. In some embodiments, the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound. In some embodiments, the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix. In some embodiments, the complexing agent comprises a cyclodextrin. In some embodiments, the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin. In some embodiments, the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin. In some embodiments, a concentration of the complexing agent is less than 200 micromolar. In some embodiments, the polymeric matrix comprises an active matrix component and an inactive matrix component. In some embodiments, the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative. In some embodiments, the active polymeric matrix component is a polymeric hydrogel. In some embodiments, the inactive polymeric matrix component is a polyolefin. In some embodiments, the polyolefin is a polyethylene, polypropylene or copolymers thereof. In some embodiments, the polyolefin is a low-density polyethylene (LDPE).
[0007] In one aspect, provided herein is a multi-dosing delivery device for dispensing a hydrophobic ophthalmic agent, the device comprising: a bottle having an extended outlet; a polymeric matrix dispensed within the extended outlet; and a reservoir configured to hold a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative, wherein the polymeric matrix is configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix. The device of claim 43, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye. In some embodiments, the activity
of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises improving visual acuity. In some embodiments, the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mm Hg. In some embodiments, the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower. In some embodiments, the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eyebelow atleast 25, 24, 23, 22, or 21 mmHg. In some embodiments, the reduction in the intraocular pressure is measured by applanation tonometry. In some embodiments, the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof. In some embodiments, the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof. In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar. In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). In some embodiments, a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w). In some embodiments, the preservative is benzalkonium chloride. In some embodiments, a concentration of the preservative is less than 0.05% (w/w). In some embodiments, the polymeric matrix is a polymeric hydrogel. In some embodiments, the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof. In some embodiments, the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2- sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM),
triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 -acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). In some embodiments, the crosslinked polyacrylamide material is isolated in the form of spherical beads. In some embodiments, the at least one modifying monomer comprises 2- acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM). In some embodiments, the solution, suspension, or emulsion further comprises a complexing agent. In some embodiments, the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound. In some embodiments, the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix. In some embodiments, the complexing agent comprises a cyclodextrin. In some embodiments, the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interiorof the cyclodextrin. In some embodiments, the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2- Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a-cyclodextrin, P- cyclodextrin, y -cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y- cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6-monodeoxy-6- N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin. In some embodiments, a concentration of the complexing agent is less than 200 micromolar. In some embodiments, the polymeric matrix comprises an active matrix component and an inactive matrix component. In some embodiments, the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative. In some embodiments, the active polymeric matrix component is a polymeric hydrogel. In some embodiments, the inactive polymeric matrix component is a polyolefin. In some embodiments, the polyolefin is a polyethylene, polypropylene or copolymers thereof. In some embodiments, the polyolefin is a low-density polyethylene (LDPE).
INCORPORATION BY REFERENCE
[0008] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative
embodiments, in which the principles of the invention are utilized, and the accompanying drawings described below.
[0010] FIG. 1 shows a study design for comparing administration of a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) to subjects.
[0011] FIG. 2 shows intraocular pressure (IOP) (mmHg) measured in subjects administered commercially available a formulation comprising latanoprost and a formulation comprising latanoprost removed by a preservative removing device (TC-002) at different time points. [0012] FIG. 3A shows a study design for comparing administration of a commercially available formulation comprising timolol (with preservative) and a formulation comprising timolol with the preservative removed by a preservative removing device to subjects.
[0013] FIG. 3B is shows mean trough intraocular pressure (IOP) (mmHg) measured at each assessment day in subjects administered a commercially available formulation comprising timolol (with preservative) and a formulation comprising timolol with the preservative removed by a preservative removing device.
[0014] FIG. 4A depicts a study design for comparing administration of a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) to subjects.
[0015] FIG. 4B shows a table of average of average intraocular pressure (IOP) (mmHg) measured at different timepoints in subjects administered a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002). Data were measured for right eye (OD) and left eye (OS).
[0016] FIG. 4C shows a table of average change in intraocular pressure (IOP) (mmHg) measured in subjects administered a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) at different timepoints relative to a baseline of the first time point, day 1 of FIG. 4B.
[0017] FIG. 4D shows average change in intraocular pressure (IOP) (mmHg) measured in subjects administered a commercially available formulation comprising latanoprost (with preservative) and a formulation comprising latanoprost removed by a preservative removing device (TC-002) at different timepoints relative to a baseline of the first time point, day 1 of FIG. 4B.
DETAILED DESCRIPTION
[0018] Intraocular pressure (IOP) of an eye may become elevated with aging, disease, or injuries, or as a side effect from a medication. Increased IOP occurs when the pressure within the eye exceeds normal limits (e.g., the normal range of 10-21 mmHg). Increased IOP is commonly associated with open -angle glaucoma and ocular hypertension and may result in damage to the optic nerve and/or permanent vision loss if left untreated. Treatment to reduce increased IOP usually includes but is not limited to medication, laser treatments, and/or surgery to decrease fluids and increase drainage in the eye.
[0019] Medications for treating increased IOP often include an ophthalmic active agent and one or more preservatives. Usually, the preservatives, such as benzalkonium chloride (BAK), allow for the medication to maintain its sterility to reduce the risk for ocular infection while allowing for a multi-dose use delivery format that can be stored at room temperature or without a need for refrigeration. However, the preservatives may cause corneal toxicity, ocular surface disease (OSD), irritation, or other unwanted side effects in the affected eyewhen administered to the affected eye. In some cases, preservative-free ophthalmic formulations may be provided as a single use packet, which can be wasteful. In some cases, the preservative-free ophthalmic formulations maybe susceptible to bacterial, fungal, or viral contamination that can have deleterious effect, including but not limited to infection, vision loss, and/or death. Thus, there is a need for devices and methods for delivering ophthalmic solution, suspension, and emulsion with little to no preservatives while maintaining the activity of the ophthalmic agent even after storage without refrigeration for long durations.
[0020] Described herein are methods and devices for dispensing an ophthalmic formulation comprising an ophthalmic agent and a preservative to treat one or more ophthalmic conditions that removes the preservative as the ophthalmic formulation is dispensed while retaining an activity of an ophthalmic agent in the dispensed formulation. Provided herein are methods and devices for dispensing an ophthalmic formulation comprising an ophthalmic agent and a preservative through a polymeric matrix that removes preservative from the ophthalmic formulation while retaining the activity of the ophthalmic formulation and providing a sterile formulation that has preservative removed. As the preservative stays in the formulation until the formulation is dispensed through a polymeric matrix, the formulation as dispensed as described herein can maintain the sterility, reduce the risk for ocular infection, allow for a multi-dose use delivery format that can be stored at room temperature or without a need for refrigeration, while reducing unwanted side effects and maintaining the activity of the ophthalmic agent once delivered to the eye. The methods and devices provided herein for removal of preservatives from
ophthalmic formulations allow for retaining the activity of the ophthalmic formulation (e.g., reduced increased IOP) and while providing a sterile formulation that has preservative removed. [0021] Provided herein are multi-dosing, preservative removing devices comprising a polymeric matrix configured such that the device maintains an ophthalmic formulation with one or more preservatives and one or more activities of the ophthalmic agent until the ophthalmic formulation is passed through the polymeric matrix. In some cases, the multi-dosing, preservative removing devices may be stored without refrigeration for at least 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months before the drug is dispensed. In some cases, ophthalmic formulation is dispensed using the multi-dosing, preservative removing device into an eye of a subject. In some cases, the ophthalmic formulation that has passed through the polymeric matrix has substantially similar activity as before passing through the polymeric matrix. In some cases, the activity of the formulation that has passed through the polymeric matrix has substantially similar activity as the formulation on day 0 of storage, even after storage without refrigeration for at least 1 week, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months. In some cases, the activity comprises reducing the increased IOP in the eye of the subject.
Ophthalmic Conditions
[0022] In some embodiments, the ophthalmic formulation provided herein may be used for the treatment of a disorder or conditions associated with elevated intraocular pressure (IOP). Conditions and disorders associated with elevated IOP can include glaucoma and ocular hypertension. Glaucoma can comprise open-angle glaucoma, closed-angle glaucoma, congenital glaucoma, or secondary glaucoma. A solution, suspension, or emulsion administered to the eye may be administered topically, for example, with an eye drop. In some embodiments, the compounds, or salts thereof, of the disclosure with low aqueous solubility may be formulated as aqueous suspensions.
[0023] In one aspect, embodiments of the present invention provide ophthalmic agents that change the levels of intraocular pressure IOP in an eye. Levels of intraocular pressure in an individual may naturally fluctuate and change. For example, at nighttime in a reclining position is associated with higher IOP than during the day in a sitting position. In some embodiments, a normal range of intraocular pressure is generally between 10 and 21 mmHg. IOP exceeding 21 mmHg is generally associated with problematic conditions. Conditions that cause elevated levels of IOP can include ocular hypertension, glaucoma, acute stress and/or anxiety. Glaucoma is a group of eye conditions that can damage the optic nerve. Glaucoma has four major types including: open-angle glaucoma, angle-closure glaucoma (or closed-angle glaucoma), congenital
glaucoma, and secondary glaucoma. Elevated IOP can also be caused by or associated with excessive aqueous production or excessive aqueous humor, inadequate aqueous drainage, eye trauma, pseudoexfoliation syndrome, pigment dispersion syndrome, and corneal arcus. Moreover, individuals can be at greater risk for developing IOP depending on myriad factors. Nonlimiting factors can include age, family history of ocular hypertension or glaucoma, ethnicity, and systemic medication. Individuals having or suspected of having an increased IOP may utilize treatment that lower pressure in the eye as provided herein .
Ophthalmic Solution, Suspension, or Emulsion
[0024] Provided herein are ophthalmic formulations comprising an ophthalmic agent and a preservative. In some embodiments, ophthalmic formulations comprise a complexing agent. In some embodiments, formulations are also referred herein as solutions, suspensions, or emulsions. In some embodiments, the solutions, suspensions, or emulsions comprise a complexing agent. In some embodiments, a solution, suspension, or emulsion may be used in any of the methods described herein. The solution, suspension, or emulsion may additionally comprise one or more pharmaceutically acceptable excipients.
[0025] Embodiments of the present disclosure may provide an ophthalmic agent for delivery to an eye. The ophthalmic agent may be a therapeutic agent for treating increased IOP. In some embodiments, the solutions, suspensions, or emulsions comprise a preservative and an ophthalmic agent. In some embodiments, the ophthalmic agent comprises a hydrophobic ophthalmic agent. In some embodiments, the solution, suspension, or emulsion comprises a complexing agent. Ophthalmic agents may comprise compounds and salts, for use in the treatment of ophthalmic diseases. Optionally, in any embodiment, the solution, suspension, or emulsion may comprise one or more pharmaceutically acceptable excipients. The disclosed compounds and salts can be used, for example, forthe treatmentor prevention of vision disorders and/or for use during ophthalmological procedures forthe prevention and/or treatment of ophthalmic disorders.
Ophthalmic Agents
[0026] In one aspect, an ophthalmic agent may be used to lower intraocular pressure. In some embodiments an ophthalmic agent to lower intraocular pressure comprises a prostaglandin or prostaglandin analog, atopical P-adrenergic antagonist, a carbonic anhydrase inhibitor, a cholinergics, an a-adrenergic agonist, a parasympathomimetic miotic agent, or combinations thereof. Nonlimiting examples of ophthalmic agents provided to lower IOP can include but are not limited to: brimonidine tartrate, aceclidine, bimatoprost, levobunolol hydrochloride, brimonidine tartrate/timolol maleate, brinzolamide, betaxolol hydrochloride, pilocarpine hydrochloride, apraclonidine, brinzolamide/brimonidine tartrate, travoprost, timolol maleate,
latanoprost, dorzolamide hydrochloride, tafluprost, latanoprostene bunod, netarsudil, apraclonidine, and dorzolamide/timolol. In some embodiments, ophthalmic agents may be used in conjunction with a compressible bottle. Ophthalmic agents may comprise brandname drugs and formulations including, but not limited to, Alphagan, Lumigan, Betagan, Combigan, Azopt, Betoptic S, Isopto Carpine, lopidine, Simbrinza, Travatan Z, Isralol, Zalatan, Trusopt, Timoptic, Ziotan, Vesneo, Vyzulta, PRX-100, Cosopt, and other agents described herein. In some embodiments the ophthalmic agent comprises latanoprost. In some embodiments the ophthalmic agent comprisestimolol. In some embodiments the ophthalmic agent comprises brinzolamide. In some embodiments the ophthalmic agent comprises brimonidine. In some embodiments the ophthalmic agent comprises travoprost. In some embodiments the ophthalmic agent comprises bimatoprost. In some embodiments the ophthalmic agent comprises netarsudil. In some embodiments the ophthalmic agent comprises latanoprost bunod. In some embodiments the ophthalmic agent comprises dorzolamide. In some embodiments the ophthalmic agent comprises aceclidine.
[0027] The ophthalmic agents may be dissolved in aqueous solution. The solution may be sterilized and buffered to appropriate pH. In some embodiments, the solution may comprise inactive ingredients such as sodium chloride, sodium citrate, hydroxy ethyl cellulose, sodium phosphate, citric acid, sodium dihydrogen phosphate, polyoxyl 40 hydrogenated castor oil, tromethamine, boric acid, mannitol, glycerine edetate disodium, sodium hydroxide, and/or hydrochloric acid. In some embodiments, the fluid comprises a preservative in addition to an ophthalmic agent. Example preservatives include but are not limited to: benzalkonium chloride (BAK), EDTA, quaternary ammonium compounds, stabilized oxychloro complexes (Purite®), solutions of borate, sorbitol, propylene glycol, and zinc (Sofzia®), etc.
[0028] Ophthalmic agents for the treatment of, for example, ocular hypertension, glaucoma, increased intraocular pressure may be administered to a patient as a solution, suspension, or emulsion delivered to an eye topically via a compressible bottle, a dropper bottle, or similar delivery mechanism. The solution, suspension, or emulsion may be subject to contamination such as microbial, fungal, or particulate contamination, which maybe adverse to patient health. In order to prevent such contamination a preservative may be added to the solution, suspension, or emulsion; however, patient exposure to preservatives may have adverse effects to eye health. It may be advantageous to limit patient exposure to preservative by providing a preservative removing device which may remove a preservative from the solution, suspension, or emulsion while maintaining the activity of the solution, suspension, or emulsion.
[0029] In some embodiments, the ophthalmic agent to be dispensed comprises an active ingredient selected from brimonidine tartrate, aceclidine, bimatoprost, levobunolol
hydrochloride, brimonidine tartrate/timolol maleate, brinzolamide, betaxolol hydrochloride, pilocarpine hydrochloride, apraclonidine, brinzolamide/brimonidine tartrate, travoprost, timolol maleate, latanoprost, dorzolamide hydrochloride, tafluprost, latanoprostene bunod, netarsudil, apraclonidine, and dorzolamide/timolol. In some embodiments, the ophthalmic agent to be dispensed comprises the active ingredient latanoprost. In some embodiments, the ophthalmic agent to be dispensed comprises the active ingredient timolol. In such embodiments, the ophthalmic agent may be an active ingredient in the treatment of elevated intraocular pressure, glaucoma, and/or ocular hypertension.
Activity of Ophthalmic Agents
[0030] In one aspect, ophthalmic agents described herein have various associated activity to treat one or more disease or disorder of the eye. In some embodiments, the ophthalmic agent comprises a hydrophobic ophthalmic agent. The activity of an ophthalmic agent can comprise changing the levels of intraocular pressure (IOP) of an eye. In some embodiments, the activity of the ophthalmic agent comprisestreating ocular hypertension or glaucoma, or a combination thereof. In some embodiments, the activity of the ophthalmic agent comprises improving visual acuity.
[0031] In some embodiments, the activity of an ophthalmic agent reduces IOP, such as by reducing IOP to about23, about 22, about21, about20, about 19, about 18, about 17, or about 16 mmHg or lower. In some embodiments, the activity of an ophthalmic agent can comprise reducing IOP to about 16 mmHg to about 23 mmHg. In some embodiments, the activity of the ophthalmic agent reduces IOP, such as by reducing IOP by at least about 1, about 2, about 3, about 4, about 5, about 6, about?, about 8, about 9, or about 10 mmHg. In some embodiments, the activity of an ophthalmic agent can comprise reducing IOP by at least about 1 mmHg to about 10 mmHg. As described herein, IOP in a healthy individual can fluctuate over the course of a day. The normal baseline for IOP is between 10 and21 mmHg. In some embodiments, the activity of the ophthalmic agent maintains IOP, such as by maintaining IOP below about 25, about 24, about 23, about 22, or about 21 mmHg. In some embodiments, the activity of the ophthalmic agent maintains IOP below about 21 mmHg to below about 25 mmHg. In some embodiments, a removal of a preservative does not substantially change the activity of the ophthalmic agent. In some embodiments, a preservative-removing device delivers an ophthalmic agent maintaining an activity sub stantially similar to a preserved ophthalmic agent.
[0032] In one aspect, a concentration of an ophthalmic agent in a solution, suspension, or emulsion of the present disclosure can be from about 0.01% (w/w) to about 1.5% (w/w), about 0.03% (w/w) to about 1.4% (w/w) about 0.05% (w/w) to about 1.3% (w/w), about 0.1% (w/w) to about 1.1 % (w/w), about 0.2% (w/w) to about 1.0 % (w/w), about 0.3% (w/w) to about 0.9%
(w/w), about 0.4% (w/w) to about 0.8% (w/w), or about 0.5% (w/w) to about 0.7% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be between 0.01% (w/w) and 0.6% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be between 0.05% (w/w) and 0.3% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion canbe less than 0.05% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be about 0.25% (w/w) to about 0.5% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be about 0.15% (w/w) to about 0.2% (w/w). In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion can be from about 1 millimolar to about 1000 millimolar, about 100 millimolar to about 900 millimolar, about 200 millimolar to about 800 millimolar, about 300 millimolar to about 700 millimolar, about 400 millimolar to about 600 millimolar, about 100 millimolar, about 200 millimolar, about 300 millimolar, about 400 millimolar, about 500 millimolar, about 600 millimolar, about 700 millimolar, about 800 millimolar, about 900 millimolar, or about 1000 millimolar. In some embodiments, the concentration of the ophthalmic agent in the solution, suspension, or emulsion is less than about 1000 millimolar, about 750 millimolar, about 500 millimolar, about 250 millimolar, or about 100 millimolar.
[0033] In some embodiments, the preservative removing device comprises a multi-dosing preservative-removal device. In some embodiments, a preservative removal device can be used multiple times to deliver an uncontaminated, preservative-free ophthalmic agent to the eye of an individual. In some embodiments, the preservative removal device can maintain the activity of the ophthalmic agent without refrigeration for a period of more than about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months or more. In some embodiments, the preservative-removal device maintains the activity of the ophthalmic agent without refrigeration for about 1 month to about 6 months or more. In some embodiments, the preservative removal device maintains the activity of the ophthalmic agent while maintaining the safety of the ophthalmic agent. In some embodiments, the preservative removing device comprises a portable device. In some embodiments, the portable device canbe held in a hand of an individual.
[0034] Activity of an ophthalmic agent canbe measured with instrumentation and/or an individual’s ability to distinguish shapesand the details of objects at given distances with corrective lenses. Methods of measuring the activity of an ophthalmic agent can comprise measurement of fluid pressure in an eye such as by using applanation tonometry (e.g., Goldmann Applanation Tonometry), non-contact tonometry or air-puff tonometry (e.g., the
ocular response analyzer), pneumotonometry (e.g., Langham ocular blood flow pneumotonometer), rebound tonometry (e.g., iCare One), dynamic contour tonometry (e.g., dynamic contour tonometer), applanation resonance tonometry (BioResonator ART), best- corrected visual acuity (BCVA), biomicroscopy (e.g., slit-lamp biomicroscopy), paychymetry, dilated ophthalmoscopy, perimetry, subject-rated drop comfort/tolerability, and/or blood samples. In some embodiments, activity of an ophthalmic agent can be measured using applanation tonometry (e.g., Goldmann Applanation Tonometry). In some embodiments, activity of an ophthalmic agent can be measured using best-corrected visual acuity (BCVA). In some embodiments, activity of an ophthalmic agent can be measured using biomicroscopy (e.g., slit-lamp biomicroscopy). In some embodiments, activity of an ophthalmic agent can be measured using applanation tonometry (e.g., paychymetry, dilated ophthalmoscopy, perimetry, subject-rated drop comfort/tolerability, and/or blood samples). In some embodiments, activity of an ophthalmic agent can be measured using paychymetry. In some embodiments, activity of an ophthalmic agent can be measured using dilated ophthalmoscopy. In some embodiments, activity of an ophthalmic agent can be measured using perimetry. In some embodiments, activity of an ophthalmic agent can be measured using subject-rated drop comfort/tolerability. In some embodiments, activity of an ophthalmic agent can be measured using blood samples of a subject. Preservative
[0035] The present disclosure provides formulations comprising one or more preservatives for solutions, suspensions, or emulsions of ophthalmic agents of the present disclosure. Preservatives may comprise compounds and salts, for use as preservatives for solutions, emulsions, or suspensions of ophthalmic agents. The one or more preservatives may for example prevent microbial and/or fungal growth causing harmful effects (e.g., permanent vision loss, death). The one or more preservatives may for example prevent physical or chemical deterioration of an ophthalmic agent.
[0036] Often, preservatives (e.g., benzalkonium chloride (BAK)) may keep products sterile, preventing microbial growth such as bacteria, fungus, and mold and reducing concerns of contamination. Usually, the use of preservatives may eliminate the need for special handling requirements which can reduce harmful environmental effects, enhance shelf life after opening, and cutback on the need to use unusual packaging. Use of preservatives may ensure the active ingredient concentration stays in solution. Furthermore, preservatives may eliminate or reduce the need for surfactants (e.g., cremophore), maintain drug concentration between doses, and eliminates the need for less favorable formulations (e.g., emulsion). On the other hand, preservatives administered to the eye of a subject can damage the ocular surface, increase inflammation, and reduce surgical success.
[0037] Non-limiting examples of preservative agents can include benzalkonium chloride, ethylenediaminetetraacetic acid(EDTA), quaternary ammonium compounds, stabilized oxychloro complexes (Purite®), solutions of borate, sorbitol, propylene glycol, and zinc (Sofzia®), etc. In some embodiments, a formulation of the disclosure comprises the preservative of quaternary ammonium compounds. In some embodiments the preservative comprises benzalkonium chloride (BAK). In some embodiments, BAK can be present in the solution, suspension, or emulsion of the ophthalmic agent at a concentration of about 0.01 mg/mL to about 0.5 mg/mL.
[0038] The Purite® preservative system includes Stabilized Oxy chloro Complex (SOC), a combination of chlorine dioxide, chlorite, and chlorate. When exposed to light, SOC dissociates into water, oxygen, sodium, and chlorine free radicals which cause oxidation of intracellular lipids and glutathione, interrupting vital enzymes for cell function and maintenance. For preservatives such as Purite® which produce chlorine free radicals, the particulate plug of the disclosure can include a material that has a high affinity for free radicals such as activated charcoal or antioxidants such as vitamin E.
[0039] The SofZia® preservative system in TravatanZ (Alcon Laboratories, Fort Worth, Texas) contains borate, sorbitol, propylene glycol, and zinc. Without intending to be bound by theory, it is believed that the preservative effect is from a combination of borate and zinc. For preservatives including borate and zinc, such as SofZia®, the particulate plug of the disclosure can include a metal chelating agent such as EDTA, anionic hydrogels that can extract cationic zinc through electrostatic interactions, cationic hydrogels or resins that can extract anionic borate ions through electrostatic interactions, or a neutralizing agent that can neutralize boric acid.
[0040] In some embodiments, removing a preservative from an ophthalmic medication may improve various signs and symptoms of OSD. In some cases, signs of OSD include but are not limited to anterior/posterior blepharitis, eczema, hyperaemia, follicles, fluorescein staining, and superficial punctuate keratitis. In some cases, symptoms of OSD include but are not limited to pain/discomfort during installation, foreign body sensations, stinging/burning sensations, dry eyes, tearing, and eyelid itching.
Complexing Agent
[0041] In some embodiments, solutions, suspensions, or emulsions of the present disclosure further comprise a complexing agent. In some embodiments, the compound or salt of an ophthalmic agent of the disclosure exhibits high affinity for the matrix material and the addition of a complexing agent reduces the affinity of the ophthalmic agent for the matrix material. In some embodiments, the solution, suspension, or emulsion comprises a cyclodextrin.
[0042] In some embodiments, the ophthalmic agent is hydrophobic. In some embodiments, a polymeric matrix material designed to absorb a preservative such as benzalkonium chloride (BAK) may also absorb a hydrophobic ophthalmic agent. A complexing agent may decrease the affinity of the ophthalmic agent for the polymeric matrix. Utilizing a complexing agent, such as cyclodextrin, may change the relative hydrophobicity (hydrophilicity) of the ophthalmic agent relative to the polymer matrix material, thereby decreasing or reducing the affinity of the ophthalmic agent for the matrix. In some embodiments, the complexing agent and the ophthalmic agent can form an inclusion compound. An inclusion compound is a complex in which one component (host) forms a cavity in which molecular entities of a second chemical species (guest) are located. In some embodiments the complexing agent is configured to host the ophthalmic agent.
[0043] In some embodiments, the cyclodextrin may be (2-hydroxypropyl)-P-cyclodextrin. The cyclodextrin may be (2-hydroxypropyl)-a-cyclodextrin, (2-hydroxypropyl)-y-cyclodextrin, a- cyclodextrin, P -cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y-cyclodextrin, or another substituted cyclic glucose polymer. In other embodiments, the cyclodextrin is chosen from dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6- monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin or a combination thereof. In other embodiments, the cyclodextrin is a randomly or selectively substituted at the hydroxyls with any chemistry and to any required degree for alpha, beta or gamma or any ring size cyclodextrin. In other embodiments other types of and degrees of substitution on the cyclodextrin rings are also known and possible. Any of these can used as complexing agents. In some embodiments commercial products are possible such as CAVASOL® W7 HP PHARMA is pharmaceutical grade hydroxypropyl -beta-cyclodextrin from Wacker Chemie AG. CAVASOL® W7 HP PHARMA is a highly soluble beta-cyclodextrin derivative.
Hydroxypropyl Betadex is another example of this same commercial type cyclodextrin. [0044] In some embodiments, the solution, suspension, or emulsion may comprise the cyclodextrin at a concentration of 127 pM (micromolar). In some embodiments, the solution, suspension, or emulsion may comprise the cyclodextrin at a concentration of greater than 1 pM, 2 pM, 5 pM, 10 pM, 20 pM, 50 pM, 100 pM, or more. In some embodiments, the solution, suspension, or emulsion may comprise the cyclodextrin at a concentration of less than 500 pM, or it may be at a concentration of about 1 mM (millimolar), 2 mM, 5 mM, 10 mM, 20 mM, 50 mM, 100 mM, or less.
[0045] In some embodiments, the complexing agent may comprise a mixture of cyclodextrins comprising one or more cyclodextrins disclosed elsewhere herein.
Excipients
[0046] Devices and methods of the present disclosure may comprise formulating the solution, suspension, or emulsion with one or more inert, pharmaceutically -acceptable excipients. Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes or micelles comprising an ophthalmic agent as disclosed herein. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, tonicity agents and other pharmaceutically -acceptable additives.
[0047] In some embodiments, solutions, suspensions, or emulsions of the present disclosure further comprise one or more physiologically acceptable carriers including excipients and auxiliaries which facilitate processing of the pharmaceutical agent into preparations which are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
[0048] Pharmaceutically acceptable carriers include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or organic esters. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The composition can also be present in a solution suitable for topical administration, such as an eye drop.
[0049] Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, hypromellose, Methocel, methyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non -toxic compatible substances employedin pharmaceutical formulations.
[0050] In some embodiments, the solutions, suspensions, or emulsions of the disclosure may include one or more additional excipients. The amount of the excipient in a pharmaceutical formulation of the disclosure canbe about 0.01% to about 1000% by mass of the compoundin the solution, suspension, or emulsion. The amount of the excipient in a solution, suspension, or
emulsion, of the disclosure canbe between 0.01% and 1000%, between 0.1% and 100%, between 1% and 50%, between 0.01% and 1%, between 10% and 100%, or between 500% and 1000% by mass of the compound in the solution, suspension, or emulsion.
[0051] The amount of the excipient in a solution, suspension, or emulsion of the present disclosure can be about 0.01% and 1000%, between 0.1% and 100%, between l% and 50%, between 0.01% and 1%, between 10% and 100, or between 500% and 1000% by mass or by volume of the unit dosage form.
[0052] The ratio of a compound of an ophthalmic agent of the present disclosure to an excipient in a pharmaceutical formulation of the present disclosure can be about 100 : about 1, about 50 : about20 : about 1, about 5 : about 1, about 1 : about 5, or about 1 : about 10. The ratio of a compound of an ophthalmic agent to an excipient in a solution, suspension, or emulsion of the present disclosure canbe within the range of between about 100 : about 1 and about 1 to about 10, between about 10 : about 1 and about 1 : about 1 , between about 5 : about 1 and about 2 : about 1 .
[0053] In some embodiments, a solution, suspension, or emulsion of the present disclosure comprises an agent for adjusting the pH of the formulation. In some embodiments, the agent for adjusting the pH could be an acid, e.g., hydrochloric acid or boric acid, or a base, e.g., sodium hydroxide or potassium hydroxide. In some embodiments, the agent for adjusting the pH is an acid such as boric acid. The formulation may comprise about 0.05 wt% to about 5 wt%, about 0.1% to about 4%, about 0.1% to about 3 wt%, about 0.1 wt% to about 2 wt%, or about 0.1 wt% to about 1 wt% of an agent for adjusting the pH.
[0054] Solutions, suspensions, or emulsions of the disclosure can be formulated at any suitable pH. In some embodiments, the pH of the solution, suspension, or emulsion comprises about 4, about4.5, about 5, about 5.5, about 6, about 6.5, about ?, about ?.5, about 8, about 8.5, or about 9 pH units. In some embodiments, the pH of the solution, suspension, or emulsion is from about 4 to about 10, about 5 to about 9, about 6 to about 8, about 7 to about 8, about 7.2 to about 7.8, about 7.3 to about 7.5, or about 7.35 to about 7.45. In some embodiments the pH of the solution, suspension, or emulsion is about 7.4.
[0055] In some embodiments, the addition of an excipient to a pharmaceutical formulation of the present disclosure can increase or decrease the viscosity of the composition by at least 5%, at at least 25%, atleast 50%, atleast 75%, at least 90%, at least 95%, or atleast 99%. In some embodiments, the addition of an excipient to a pharmaceutical formulation of the present disclosure can increase or decrease the viscosity of the composition by no greater than 5%, no greaterthan 25%, no greaterthan 50%, no greater than 75%, nogreaterthan 90%, no greater
than 95%, or no greater than 99%. Examples of ranges which the viscosity change falls within can be created by combining any two of the preceding percentages (e.g., by 5% to 99%) [0056] In some embodiments, an excipient that increases a viscosity may comprise polyvinyl alcohol, poloxamers, hyaluronic acid, carbomers, and polysaccharides, that is, cellulose derivatives, hydroxymethyl cellulose, hypromellose, Methacel, gellan gum, and xanthangum. In some embodiments, an excipient that increases mucoadhesive properties may be added. Excipients that increase mucoadhesion may include polyacrylic acid, hyaluronic acid, sodium carboxymethyl cellulose, lectins, and chitosan.
[0057] In some embodiments, solutions, suspensions, or emulsions of the present disclosure further comprise an agent for adjusting the osmolarity of the solution, suspension, or emulsion, e.g., mannitol, sodium chloride, sodium sulfate, dextrose, potassium chloride, glycerin, propylene glycol, calcium chloride, and magnesium chloride. In some embodiments, the solution, suspension, or emulsion comprises from about 0.1 wt% to about 10 wt%, about 1 wt% to about 5 wt%, about 1 wt% to about 4 wt%, or about 1 wt% to about 3 wt% of an agent for adjusting the osmolarity of the solution, suspension, or emulsion. In some embodiments, the solution, suspension, or emulsion of the disclosure has an osmolarity from about 10 mOsmto about 1000 mOsm, about200 mOsm to about400mOsm, about250mOsm to about350 mOsm or about 290 mOsm to about 310m Osm.
[0058] In some embodiments, solutions, suspensions, or emulsions of the present disclosure further comprise a buffering agent, such as tromethamine, potassium phosphate, sodium phosphate, saline sodium citrate buffer (SSC), acetate, saline, physiological saline, phosphate buffer saline(PBS), 4-2-hydroxyethyl-l -piperazineethanesulfonic acid buffer (HEPES), 3-(N- morpholinojpropanesulfonic acid buffer (MOPS), and piperazine -N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), sodium acetate-boric acid stock solution, boric acid-sodium carbonate with sodium chloride solution, boric acid-sodium borate buffer, sodium and potassium phosphate buffers, boric acid-sodium carbonate with potassium chloride, or combinations thereof. In some embodiments, the solution, suspension, or emulsion comprises from about 0.05 wt% to about 5 wt%, about 0.1 wt% to about 4 wt%, about 0.1 wt% to about 3 wt%, about 0.1 wt% to about 2 wt%, or about 0.1 wt% to about 1 wt% of an agent for buffering the solution, suspension, or emulsion.
[0059] In some embodiments, the solution emulsion or suspension provided herein comprises an alcohol as an excipient. Non-limiting examples of alcohols include ethanol, propylene glycol, glycerol, polyethylene glycol, chlorobutanol, isopropanol, xylitol, sorbitol, maltitol, erythritol, threitol, arabitol, ribitol, mannitol, galactilol, fucitol, lactitol, and combinations thereof.
Salts
[0060] Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p -toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt is chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
[0061] The compounds may be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials. Synthetic chemistry transformations and methodologies useful in synthesizing the compounds described herein are known in the art.
[0062] The present disclosure provides salts of any one or both of an ophthalmic agent and a preservative. Pharmaceutically-acceptable salts include, for example, acid-addition salts and base-addition salts. The acid that is added to the compound to form an acid-addition salt can be an organic acid or an inorganic acid. A base that is added to the compound to form a base- addition salt can be an organic base or an inorganic base. In some embodiments, a pharmaceutically-acceptable salt is a metal salt.
[0063] Metal salts can arise from the addition of an inorganic base to a compound of the present disclosure. The inorganic base consists of a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
[0064] In some embodiments, a metal salt is an ammonium salt, a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a
calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.
[0065] Ammonium salts can arise from the addition of ammonia or an organic amine to a compound of the present disclosure. In some embodiments, the organic amine is triethyl amine, diisopropyl amine, ethanol amine, diethanol amine, triethanol amine, morpholine, N- methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, pipyrazole, imidazole, pyrazine, or pipyrazine.
[0066] In some embodiments, an ammonium salt is a triethyl amine salt, a diisopropyl amine salt, an ethanol amine salt, a diethanol amine salt, a triethanol amine salt, a morpholine salt, an N-methylmorpholine salt, a piperidine salt, an N-methylpiperidine salt, an N-ethylpiperidine salt, a dibenzylamine salt, a piperazine salt, a pyridine salt, a pyrazole salt, an imidazole salt, or a pyrazine salt.
[0067] Acid addition salts can arise from the addition of an acid to a compound of the present disclosure. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p -toluenesulfonic acid, citric acid, oxalic acid, or maleic acid. [0068] In some embodiments, the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt, a sulfite salt, a phosphate salt, isonicotinate salt, a lactate salt, a salicylate salt, a tartrate salt, an ascorbate salt, a gentisinate salt, a gluconate salt, a glucuronate salt, a saccharate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a methanesulfonate (mesylate) salt, an ethanesulfonate salt, a benzenesulfonate salt, a p -toluenesulfonate salt, a citrate salt, an oxalate salt , or a maleate salt. [0069] The methods and formulations described herein include the use of amorphous forms as well as crystalline forms (also known as polymorphs). Active metabolites of compounds or salts of any one of the compounds of the present disclosure having the same type of activity are included in the scope of the present disclosure. In addition, the compounds described herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. The solvated forms of the compounds and salts presented herein are also considered to be disclosed herein.
[0070] In some embodiments, an aqueous solutions, emulsions, or suspensions of the disclosure comprises at least 90 wt% water, such as at least 91 wt%, at least 92 wt%, at least 93 wt%, at least 94 wt%, at least 95 wt%, at least 96 wt%, at least 97 wt%, at least 98 wt%, or even at least 99 wt % of water.
Polymeric Matrix
[0071] The present disclosure provides a preservative removal agent (e.g. a matrix). In some embodiments, the preservative removal agent comprises a polymeric matrix. A preservative removal agent may rapidly and selectively remove preservatives of the present disclosure from a solution, suspension, or emulsion comprising an ophthalmic agent. The preservative removal agent may rapidly and selectively extract the preservative, allowing the eye drop formulation to flow through the plug with minimal pressure drop, yet with sufficient time to remove the preservative and with sufficient surface area and chemistry to adsorb the preservative. The matrix may comprise a material with a high affinity for the preservative, such as for example benzalkonium chloride (BAK), and at the same time a low affinity for a drug or other ophthalmological agent especially in some embodiments of this invention where the drug is also in the complex with a complexing or capping agent. The preservative removal agent may be sufficiently selective, such that at least 50 percent of the preservative may be removed and at least 50 percent of the drug may be retained by the solution. BAK (benzalkonium chloride) can also go under a number of synonyms: alkylbenzyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, benzyl ammonium chloride to name a few. It is also defined by a structure such as Formula: C6H5CH2N(CH3)2RC1 (R=C8H17 to CI8H37) with a CAS Number: 63449-41-2. For most purposes in ophthalmic applications and formulations PharmaGrade, EP, USP, JP, manufactured under appropriate GMP controls for pharma or biopharmaceutical production is used.
[0072] Non-limiting examples of a preservative removal agents may comprise solid, gel, and/or particulate matrices. The preservative removal agent may act as a physical barrier or filter. Additionally, or alternatively, the preservative removal agent may chemically remove a preservative such as by adsorption of the preservative onto the matrix. The preservative removal agent may be disposed in the outlet of a container, which container may contain the solution, suspension, or emulsion.
[0073] In some embodiments, a matrix disposed within a nozzle may be a porous polymeric matrix. The porous polymeric matrix may comprise a variety of materials. Such material may be safe and biocompatible. Such material may comprise but is not limited to, for example, Poly(2 -hydroxy ethyl methacrylate) (pHEMA), poly(hydroxylethyl methacrylate-co-methacrylic
acid), crosslinked polyacrylamide, dimethyl acrylamide, methyl methacrylate, silicones, and/or any combination of the preceding materials.
[0074] In some embodiments, the matrix may be highly porous. The pore size in the matrix may be small enough so that the molecules, which may initially be far from the surface of the polymer in the matrix, may diffuse towards the polymer and adsorb. A matrix may have large interconnected pores which may allow flow of solution and adsorption of the preservative into the pores. The matrix may be formed as a porous gel, as a packed bed, and/or a structure formed by 3D printing soft lithography, electrospinning, or any other appropriate method. In some embodiments, the matrix may comprise a microporous gel. In some embodiments, the matrix may comprise a packed bed of pHEMA or crosslinked polyacrylamide or other polymeric particles. The particles may be macroporous. The particles may be spherical or non-spherical. In some embodiments, the polymeric matrix may comprise nano or micron sized polymeric particles (e.g., nanogels or microgels). In some embodiments, the polymeric matrix may comprise a cryogel. In some embodiments, the polymeric matrix may be termed a hydrogel, be hydrophilic and absorb water readily. In some embodiments, the particles themselves may directly impart the preservative effect, such as colloidal silver nanoparticles.
[0075] In certain embodiments, particles of the formulations described herein have an average diameter from about 1 nm to about 10 pm, about 1 nm to about 10 pm, about 1 nm to about 5 pm, about 1 nm to about 2 pm, about 1 nm to about 1 pm, about 1 nm to about 900 nm, about 1 nm to about 800 nm, about 1 nm to about 700, about 1 nm to about 600 nm, about 1 nm to about 500 nm, about 1 nm to about 400 nm, about 1 nm to about 300 nm, about 1 nm to about 200 nm, or even from about 1 nm to about 100 nm. In certain embodiments, the average diameter is the average largest diameter or the average equivalent diameter.
[0076] In certain embodiments, greater than 80% of the particles, such as greater than 90% or greater than 95% of the particles in the formulation have an average largest particle diameter of from about 1 nm to about 1000 pm, about 1 nm to about 10 pm, about 1 nm to about 5 pm, about 1 nm to about 2 pm, about 1 nm to about 1 pm, about 1 nm to about 900 nm, about 1 nm to about 800 nm, about 1 nm to about 700, about 1 nm to about 600 nm, about 1 nm to about 500 nm, about 1 nm to about 400 nm, about 1 nm to about 300 nm, about 1 nm to about 200 nm, or even from about 1 nm to about 100 nm. In certain embodiments, the average diameter is the average largest diameter or the average equivalent diameter.
[0077] In certain embodiments, particles of the porous polymeric matrix described herein have an average diameter from about 100 nm to about 10 pm, about lOO nm to about 10 pm, about 100 nm to about 5 pm, about lOO nm to about 2 pm, about lOO nm to about 1 pm, about 100 nm to about 900 nm, about 100 nm to about 800 nm, about 100 nm to about 700, about 100 nm to
about 600 nm, about 200 nmto about 500 nm, about 250 nm to about 600 nm, about 300 nm to about 600 nm, about 350 nmto about 700 nm, about 450 nm to about 550 nm, about 475 nm to about 525 nm, or from about 400 nm to about 700 nm. In certain embodiments, the average diameter is the average largest diameter or the average equivalent diameter.
[0078] In certain embodiments, greater than 80% of the particles of the porous polymeric matrix, greater than 90% of the particles of the porous polymeric matrix, or greater than 95% of the particles of the porous polymeric matrix have an average diameter from about 100 nm to about 10 pm, about 100 nm to about 10 pm, about 100 nmto about 5 pm, about 100 nm to about 2 pm, about 100 nm to about 1 pm, about lOOnm to about 900 nm, about lOOnm to about 800 nm, about 100 nm to about 700, about 100 nm to about 600 nm, about 200 nm to about 500 nm, about 250 nm to about 600 nm, about 300 nm to about 600 nm, about 350 nm to about 700 nm, about 450 nm to about 550 nm, about 475 nm to about 525 nm, or from about 400 nm to about 700 nm. In certain embodiments, the average diameter is the average largest diameter or the average equivalent diameter.
[0079] In certain embodiments, greater than 80% of the particles of the porous polymeric matrix, greater than 90% of the particles of the porous polymeric matrix, or greater than 95% of the particles in the formulation have an average diameter from about 10 pm to about 100 pm, about 50 pm to about 200 pm, about 90 pm to about 180 pm, about 150 pm to about 250 pm, about 200 pm to about 350 pm about 250 pm to about 500 pm , about 350 pm to about 800 pm, about 500 pm to about 1000 pm In certain embodiments, the average diameter is the average largest diameter or the average equivalent diameter. The particles may be irregular, regular, spherical, ovoid, or generally of any shape and the size can be defined as passing through a certain sized screen sieve.
[0080] The matrix may comprise a tortuosity such that the flow path of a solution, suspension, or emulsion through the nozzle maybe significantly increased. In an embodiment where the matrix is a packed bed of macroporous particles, the packed beds of macroporous particles may have three levels of porosity: the spacebetween the particles, the macropores in the particles, and the inherent porosity of the polymer. In such an embodiment, all three levels of porosity may contribute to the tortuosity of the matrix.
[0081] In some embodiments, a matrix disposed within a nozzle may be a porous polymeric matrix. Applying a pressure behind the nozzle may cause fluid to flow through the nozzle via the flow path, along which path the preservative may be removed by adsorption onto the matrix. The polymer material, the hydraulic permeability, the partition coefficient, the adsorption rate, and the pore size in combination may aid in the absorption of all or most of the preservative from the solution and thus patient eye drops. The reduced preservative solution may
subsequently be delivered directly to the eye. The porous polymeric matrix may rapidly and selectively extract the preservative, allowing the eye drop formulation to flow through the plug with minimal pressure drop, yet with sufficient time to remove the preservative and with sufficient surface area to adsorb the preservative. The matrix may comprise a material with a high affinity for the preservative, such as for example benzalkonium chloride (BAK), and low affinity for a drug or other ophthalmological agent. The porous polymeric matrix may comprise a high affinity for the preservative, such that at least 50 percent of the preservative may be removed and at least 50 percent of the drug may be retained by the solution.
[0082] The porous polymeric matrix may comprise a variety of materials. Such material are safe and biocompatible. A polymer of the present disclosure may comprise various monomers, for example, Poly(2 -hydroxy ethyl methacrylate) (pHEMA) and/or and/or acrylamide (AM), dimethyl acrylamide (DMA) and/or methyl methacrylate (MMA) and/or N-Vinylpyrrolidone (NVP) and/or 2-acrylamido-2-methylpropane sulfonic acid (AMPS) and/or polyvinyl alcohol (PVA) and/or polymethylpropane sulfonic acid (PAMPS) and/or 2-sulfoethyl methacrylate (SEM) and/or acrylic acid (AA) and/or vinylphosphonic acid (VP) and/or t-butyl methacrylate (TBM) and/or Methacryloxypropyltris(trimethylsiloxy)silane (TRIS) and/or t-amyl methacrylate and/or n-octyl methacrylate and/or iso-decyl methacrylate and/or n-decyl methacrylate and/or n- dodecyl acrylate and/or n-hexyl acrylate and/or n-dodecyl acrylate and/or N-(n- Octadecyl)acrylamide and/or silicones and/or any combination of the preceding materials. The polymeric matrix may further comprise a cross linker. A crosslinker may comprise N,N’- methylenebis(acrylamide) (MB AM) and/or triacrylamido triazine (TATZ) and/or SR 351 and/or SR9035 and/or any combination of the preceding materials.
[0083] In some embodiments, the matrix material comprises a copolymer. A copolymer may comprise more than one species of monomer. Copolymers may be branched. Copolymers may be linear. Copolymers may comprise crosslinkers. Copolymers may be block copolymers, may be alternating copolymers, may be periodic copolymers, may be gradient copolymers may be statistical copolymers, may be stereoblock copolymers. The copolymers may exhibit phases of differing hydrophobicity or hydrophilicity. The hydrophobicity and/or hydrophilicity of the one or more monomers or cross-linkers may control the binding of a therapeutic agent or a preservative to the plug material.
[0084] In some embodiments, the polymeric matrix comprises polyvinyl alcohol crosslinked with citric acid or other suitable crosslinking agent to render it a hydrophilic hydrogel. In some embodiments, the polymeric matrix can be crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid,
polyacrylic acid and copolymers such as poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide).
[0085] Polymers of the present disclosure may generally follow an A/B/C formula where A and B are monomers, C is one or more cross-linkers, and A and B are not the same monomer. In some examples, A may be an anionic hydrophilic monomer. In an A/B/C formula, monomers of type A may comprise AM or NVP. In some examples, B may be an ionic hydrophilic monomer. In an A/B/C formula, monomers of typeB may comprise MAA, AMPS, SEM, AA, or VP. In some examples, C may be a crosslinker. In an A/B/C formula, monomers of type C may comprise one or more of MB AM, TATZ, or SR 351. Polymers of the present disclosure may generally follow an A/C formula where A is a monomer as described above and C is one or more cross-linkers as described above. Polymers of the present disclosure may generally follow an B/C formula where B is a monomer as described above and C is one or more cross-linkers as described above.
[0086] Polymers of the present disclosure may also comprise grafted copolymers such that components such as monomer A and with a cross-linker C are first copolymerized to form a crosslinked copolymer that can be isolated as a small bead or other shaped particle. In some embodiments, the beads comprise spherical beads. These beads or particles can then be reswollen in water and a monomer of B type can added and then polymerized into or onto the bead or particle through the use a free radical “grafting” polymerization. In this embodiment the particles are made up of A/C copolymer with a “grafted” B polymer as part of the copolymer structure.
[0087] The following is a non-exhaustive list of examples of polymers of the present disclosure. The following includes polymer components and percent compositions, separated by slashes, respectively. Polymers of the present disclosure may comprise: AMPS/MBAM/TATZ 7.5/82.5/10, AMPS/MBAM/TATZ 7.5/77.5/15 AMPS/MBAM 7.5/92.5, BioRadBeads /AMPS 1 g/0.5, AMPS/MBAM 7.5/92.5, AMPS/MBAM/TATZ 7.5/87.5/5.0 (D-322-006-AW), SEM/MBAM 7.5/92.5, AM/2-Sulfoethyl MA(SEM)/MBAM 30/10/60, AMPS/MBAM 7.5/92.5; AMPS/MBAM 7.5/92.5, AMPS/MBAM 7.5/92.5, AMPS/MBAM 7.5/92.5, PVA/PAMPS/C A 4.8/1 .2/2.4 IPN, AMPS/MBAM 7.5/92.5 ISP, NVP/AMPS/MBAM/TATZ 30/10/30/30, AMPS/MBAM 7.5/92.5, N-vinylpyrrolidinone/AMPS/MB AM 30/10/60, AA/SR351 40/60, AA/MBAM/SR35 1 60/30/10, AM/2- Sulfoethyl MA (SEM)/MBAM 15/25/60, AA/MBAM 40/60, AA/MBAM 50/50, and VP/AA/MB AM 10/45/45.
[0088] Any matrix material and any drug in association with a complexing agent may be used such that the drug/complex partition coefficient into the matrix may be lower by at least an order of magnitude or 2 orders of magnitude than the matrix’s affinity for the preservative. For
example, pHEMA, or S03- or P03H- or COO- groups on the polymer (or matrix) may bind BAK with a partition coefficient of about 100-500, or in some embodiments, 1000 depending on the BAK concentration and the structure of the matrix and the % content of those groups. In some embodiments, the matrix may comprise a partition coefficient for the preservative from the solution, suspension, or emulsion of, for example, at least 10, at least 100, at least 1000, at least 10,000, or within a range defined by any two of the preceding values. Additionally, or alternatively, the adsorption rate constant may be sufficiently high so that the time for adsorption of a drug molecule to the polymer may be less than the time to form a drop. The time to form a drop may comprise a time within a range from 0.1 to 10 seconds.
[0089] The matrix may display a high hydraulic permeability such that relatively little pressure may be required to dispense a fluid. The hydraulic permeability may depend on the design of the filter. Larger pores in the matrix may allow for higher flow for a given pressure drop. In some embodiments, hydraulic permeability may be larger than about 0.01 Darcy (Da). A nozzle may comprise a permeability of about 0.1 Darcy. A hydraulic permeability of 1 to 10 Darcy may allow fluid to be retained in the filter during instances when the pressure may be lowered sub sequent to formation of a drop. A larger hydraulic permeability may allow the same plug to work for a wide range of formulations including, for example, high viscosity formulations, such as rewetting eye drops. In some embodiments, the porous polymeric matrix comprises a hydraulic permeability of, for example, 0.01 Da, 0.1 Da, 1 Da, 10 Da, 100 Da, 1000 Da or a hydraulic permeability within a range defined by any two of the preceding values.
[0090] In some embodiments, the matrix may be highly porous. The pore size in the matrix may be small enough so that the molecules, which may initially be far from the surface of the polymer in the matrix, may diffuse towards the polymer and adsorb. A matrix may comprise large interconnected pores which may allow flow of solution and adsorption of the preservative into the pores. The matrix may be formed as a porous gel, as a packed bed, and/or a structure formed by 3D printing soft lithography, electrospinning of a fiber, or any other appropriate method. In some embodiments, the matrix may comprise a microporous gel. In some embodiments, the matrix may comprise a packed bed of pHEMA or crosslinked polyacrylamide with an anionic moiety or functionality as part of the polymer or other polymeric particles. The particles may be macroporous. The particles may be spherical or non-spherical. In some embodiments, the polymeric matrix may comprise nano or micron sized or 10s of microns or 100s of microns of polymeric particles (e.g., nanogels or microgels). In some embodiments, the polymeric matrix may comprise a cryogel. In some embodiments, the particles themselves may directly impart the preservative effect, such as colloidal silver nanoparticles.
[0091] In some embodiments, the particles may need to be stably held in the nozzle and prevented from eluting from the nozzle. The particles may be attached to the container walls through long polymeric chains and/or by placing a filter at the exit from the device. Additionally, or alternatively, the walls of the container or other surfaces may comprise preservative attached thereupon and/or incorporated therein. In such embodiments, the preservative source comprises a pHEMA membrane with 1 -10% by volume equilibrated with BAK. In some embodiments, the matrix comprises pre-loaded with BAK at a concentration to inhibit microbial growth over time.
[0092] In some embodiments, the porous matrix material may comprise a tortuosity such that the flow path of a solution, suspension, or emulsion through the nozzle increases. In some embodiments where the matrix comprises a packed bed of macroporous particles, the packed beds of macroporous particles may comprise three levels of porosity: the space between the particles, the macropores in the particles, and the inherent porosity of the polymer. In such embodiments, all three levels of porosity may contribute to the tortuosity of the matrix. The tortuosity of the porous material combined with the geometry nozzle itself may increase the flow path in accordance with a multiplicative factor of a first flow path length corresponding to flow defined by the nozzle geometry and a second flow path length corresponding to the tortuosity of the porous material.
[0093] The pressure needed for drop creation may exceed the Young Laplace pressure during drop creation, which may be about 2o/R.d where c is the surface tension and Rd is the radius of the drop. Estimating Rd~ 0.5 mm based on a drop volume of 30 pL, and using the surface tension of water may yield a Young Laplace pressure of about lOOPa. The pressure to form a drop may additionally exceed the pressure needed to displace 30 pL of volume. Typical drop volumes may comprise a volume within a range between 1 pL and 100 pL. The minimum pressure to form a drop may be ~ 0.01 Atm (1000 Pa) based on an ideal gas estimate using a 3mLbottle at atmospheric pressure, but may be lower for larger bottles at varying pressures. Maximum pressure to form a drop may be limited by a patient strength. The pressure to form a drop may be within a range between 0.01 Atm and 0.5 Atm.
[0094] The rate of liquid flow through the plug may depend on the applied pressure as well as the design parameters of the matrix including, but not limited to, length, area, porosity, hydraulic permeability, flow path length, etc. These design parameters may be considered individually or in combination to remove preservative without excessive squeeze pressure. The rate of liquid flow may affect the time to form a drop.
[0095] A solution, suspension, or emulsion can comprise an ophthalmic agent and a preservative. In one aspect, a polymeric matrix is configured such that the preservative maybe
selectively removedin the solution, suspension, or emulsion after passing through the polymeric matrix. In some embodiments, the polymeric matrix may be configured such that about 1% to about 99%, about 20% to about 80%, about 40% to about 60%, about 10%, about 20%, about 30%, about40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the preservative is selectively removedin the solution, suspension, or emulsion after passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than about 50%, 40%, 30%, 20%, 10%, or 5% of the preservative. In some embodiments, the ophthalmic agent comprises a hydrophobic ophthalmic agent. In some embodiments, the preservative comprises benzalkonium chloride (BAK).
[0096] As described herein, ophthalmic agents have an associated activity (e.g., lowering intraocular pressure (IOP)). A solution, suspension, or emulsion can comprise an ophthalmic agent and a preservative. In one aspect, a polymeric matrix is configured such that an activity of the ophthalmic agent is substantially maintained in the solution, suspension, or emulsion after passing through the polymeric matrix. In some embodiments, the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least about 30% to about 95%, about 40% to about 80%, about 50% to about 70%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 95% of an activity of the ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0097] In one aspect, a polymeric matrix can comprise an active matrix component and an inactive matrix component. In some embodiments, the inactive matrix component can have substantially no affinity for the ophthalmic agent or the preservative. In some embodiments the active polymeric matrix component comprises polymeric hydrogel. In some embodiments, the inactive polymeric matrix component is a polyolefin. In some embodiments, inactive polymeric matrix component can comprise a polyethylene, polypropylene, or copolymers thereof. In some embodiments the inactive polymeric matrix component can comprise a low-density polyethylene (LDPE).
Compressible Bottle
[0098] In one aspect, a solution, suspension, or emulsion can be disposed within a chamber of a compressible bottle. In some embodiments, a compressible bottle can comprise an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding the solution, suspension, or emulsion. In some embodiments, the solution, suspension, or emulsion comprises an ophthalmic agent. In some embodiments, the solution, suspension, or emulsion may further comprise a preservative. In some embodiments, applying pressure to the compressible bottle
passes the solution, suspension, or emulsion through the polymeric matrix to the outlet. In some embodiments, applying pressure to the compressible bottle forms a drop at the outlet. In some embodiments, the drop comprises the solution, suspension, or emulsion. In some embodiments, the compressible bottle comprises a multi -dosing device.
[0099] In some embodiment, compressible bottle comprises a portable device. In some embodiments, the compressible bottle can be held in a hand of an individual. In some embodiments, the compressible bottle comprises a mass of less than about 100 grams, about 90 grams, about 80 grams, about 70 grams, about 60 grams, about 50 grams, about 40 grams, about 30 grams, about 20 grams, about 10 grams, or about 5 grams. In some embodiments the mass of the compressible bottle can be between about 2 grams and about 100 grams.
Dosage
[0100] The dosage and frequency (single or multiple doses) administered to a mammal may vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health -related problems. Other therapeutic regimens or agents may be used in conjunction with the methods and compounds of this disclosure. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
[0101] Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present disclosure should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dose also may be determined by the existence, nature, and extent of any adverse side effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals may be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This may provide a therapeutic regimen that is commensurate with the severity of the individual's disease state
Definitions
[0102] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference.
[0103] As used in the specification and claims, the singular form “a”, “an” and “the” includes plural referencesunless the context clearly dictates otherwise.
[0104] As used herein, and unless otherwise specified, the term "about" or "approximately" means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on howthe value is measured or determined. In certain embodiments, the term "about" or "approximately" means within 1 , 2, 3, or 4 standard deviations. In certain embodiments, the term "about" or "approximately" means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range. In certain embodiments, the term "about" or "approximately" means within 40.0 mm, 30.0 mm, 20.0 mm, 10.0mm 5.0 mm 1 .0 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm or 0. 1 mm of a given value or range.
[0105] As used herein, the term “OD” refers to right eye of a subject.
[0106] As used herein, the term “OS” refers to left eye of a subject.
[0107] As used herein, the terms “comprises,” “comprising,” or any other variation there of, are intended to cover a nonexclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
[0108] As used herein, the terms “user”, “subject” or “patient” are used interchangeably. As used herein, the terms “subject” and “subjects” refers to an animal (e.g., birds, reptiles, and mammals), a mammal including a primate (e.g., a monkey, chimpanzee, and a human) and a non-primate (e.g., a camel, donkey, zebra, cow, pig, horse, cat, dog, rat, and mouse). In certain embodiments, the mammal is 0 to 6 months old, 6 to 12 months old, 1 to 5 years old, 5 to 10 years old, 10 to 15 years old, 15 to 20 years old, 20 to 25 years old, 25 to 30 years old, 30 to 35 years old, 35 to 40 years old, 40 to 45 years old, 45 to 50 years old, 50 to 55 years old, 55 to 60 years old, 60 to 65 years old, 65 to 70 years old, 70 to 75 years old, 75 to 80 years old, 80 to 85 years old, 85 to 90 years old, 90 to 95 years old or 95 to 100. In some embodiments, the subject or patient is a pig. In certain embodiments, the pig is 0 to 6 months old, 6 to 12 months old, 1 to 5 years old, 5 to 10 years old or 10 to 15 years old. The natural lifespan of a pig is 10-15 years. [0109] The terms “treating” or “treatment” refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient’s physical or mental well-being. The treatment or amelioration of symptoms may be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams,
and/or a psychiatric evaluation. The term "treating" and conjugations thereof, include prevention of an injury, pathology, condition, or disease.
[0110] In some embodiments, the term “prevent” or “preventing” as related to a disease or disorder may refer to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
[0111] An “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g. achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, or reduce one or more symptoms of a disease or condition). An example of a “therapeutically effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.” A “reduction of’ a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). The exact amounts may depend on the purpose of the treatment and may be ascertainable by one skilled in the art using known techniques. [0112] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[0113] The term “activity” when describing an ophthalmic agent herein refers to treatment provided by an ophthalmic agent (e.g., lowering intraocular pressure (IOP) of an eye) to a symptom or a sign of a disorder or a condition. In some case, the treatment comprises reducing the symptom or a sign of a disorder or a condition in a subj ect having the disorder or the condition.
[0114] The term “safety” when describing an ophthalmic agent, an ophthalmic formulation, or a solution, suspension, or emulsion herein refers to a characteristic that protects against harmful contamination (e.g., fungal or bacterial contamination).
[0115] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons or heteroatoms of the structure. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom andthe substituent, andthatthe substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by
rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad asp ect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
NUMBERED EMBODIMENTS
[0116] Embodiment 1. A method for providing a hydrophobic ophthalmic agent comprising: providing a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and providing a polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix. [0117] Embodiment 2. A method for providing an ophthalmic agent comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
[0118] Embodiment 3. A method for delivering a hydrophobic ophthalmic agent to an eye of a subject to reduce intraocular pressure comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
[0119] Embodiment 4. The method of any one of preceding embodiments, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing
through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0120] Embodiment 5. The method of any one of preceding embodiments, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0121] Embodiment 6. The method of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
[0122] Embodiment 7. The method of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof.
[0123] Embodiment 8. The method of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises improving visual acuity.
[0124] Embodiment 9. The method of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg.
[0125] Embodiment 10. The method of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower.
[0126] Embodiment 11. The method of any one of the preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
[0127] Embodiment 12. The method of any one of preceding embodiments, wherein the reduction in the intraocular pressure is measured by applanation tonometry.
[0128] Embodiment 13. The method of any one of preceding embodiments, wherein the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0129] Embodiment 14. The method of any one of the preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or21 mmHg.
[0130] Embodiment 15. The method of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine,
travoprost, bimatoprost, netarsudil, latanoprostbunod, dorzolamide, or aceclidine, ora combination thereof.
[0131] Embodiment 16. The method of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
[0132] Embodiment 17. The method of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
[0133] Embodiment 18. The method of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). [0134] Embodiment 19. The method of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). [0135] Embodiment 20. The method of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). [0136] Embodiment 21. The method of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w).
[0137] Embodiment 22. The method of any one of preceding embodiments, wherein the preservative is benzalkonium chloride.
[0138] Embodiment 23. The method of any one of preceding embodiments, where a concentration of the preservative is less than 0.05% (w/w).
[0139] Embodiment 24. The method of any one of preceding embodiments, wherein the polymeric matrix is a polymeric hydrogel.
[0140] Embodiment 25. The method of any one of preceding embodiments, wherein the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co- acrylamide), or a combination thereof.
[0141] Embodiment 26. The method of any one of preceding embodiments, wherein the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’ -methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 - acrylamido-2-methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
[0142] Embodiment 27. The method of any one of preceding embodiments, wherein the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one
crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). [0143] Embodiment 28. The method of embodiment 27, wherein the crosslinked polyacrylamide material is isolated in the form of spherical beads.
[0144] Embodiment 29. The method of embodiment 27 or embodiment 28, wherein the at least one modifying monomer comprises 2-acrylamido-2 -methylpropane sulfonic acid (AMPS) or 2- sulfoethyl methacrylate (SEM).
[0145] Embodiment 30. The method of any one of preceding embodiments, wherein the solution, suspension, or emulsion further comprises a complexing agent.
[0146] Embodiments 1. The method of embodiment 30, wherein the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
[0147] Embodiment32. The method of embodiment 30, wherein the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix. [0148] Embodiment 33. The method of embodiment 30, wherein the complexing agent comprises a cyclodextrin.
[0149] Embodiment34. The method of embodiment 33, wherein the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin.
[0150] Embodiment35. The method of embodiment 33, wherein the cyclodextrin is atleastone of (2-Hydroxypropyl)-a-cyclodextrin, (2-Hydroxypropyl)-P-cyclodextrin, (2 -Hydroxyprop yl)-y- cyclodextrin, a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P- cyclodextrin, methyl-y-cyclodextrin, dimethyl -beta-cyclodextrin, highly sulphated-beta- cyclodextrin, 6-monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin.
[0151] Embodiment 36. The method of embodiment 30, wherein a concentration of the complexing agent is less than 200 micromolar.
[0152] Embodiment 37. The method of any one of preceding embodiments, wherein the polymeric matrix comprises an active matrix component and an inactive matrix component. [0153] Embodiment38. The method of embodiment 37, wherein the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
[0154] Embodiment 39. The method of embodiment 37 or embodiment 38, wherein the active polymeric matrix component is a polymeric hydrogel.
[0155] Embodiment 40. The method of embodiments? or embodiment 38, wherein the inactive polymeric matrix component is a polyolefin.
[0156] Embodiment 41. The method of embodiment 40, wherein the polyolefin is a polyethylene, polypropylene or copolymers thereof.
[0157] Embodiment 42. The method of embodiment 41, wherein the polyolefin is a low-density polyethylene (LDPE).
[0158] Embodiment 43. A multi-dosing delivery device for dispensing a hydrophobic ophthalmic agent, the device comprising: a bottle having an extended outlet; a polymeric matrix dispensed within the extended outlet; and a reservoir configured to hold a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative, wherein the polymeric matrix is configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
[0159] Embodiment 44. The device of embodiment 43, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0160] Embodiment 45. The device of embodiment 43 or embodiment 44, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0161] Embodiment 46. The device of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
[0162] Embodiment 47. The device of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof.
[0163] Embodiment 48. The device of any one of preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises improving visual acuity.
[0164] Embodiment 49. The device of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mm Hg.
[0165] Embodiment 50. The device of any one of preceding embodiments, wherein the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower.
[0166] Embodiment 51. The device of any one of the preceding embodiments, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
[0167] Embodiment 52. The device of any one of preceding embodiments, wherein the reduction in the intraocular pressure is measured by applanation tonometry.
[0168] Embodiment 53. The device of any one of preceding embodiments, wherein the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
[0169] Embodiment 54. The device of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprost bunod, dorzolamide, or aceclidine, or a combination thereof.
[0170] Embodiment 55. The device of any one of preceding embodiments, wherein the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
[0171] Embodiment 56. The device of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
[0172] Embodiment 57. The device of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w). [0173] Embodiment 58. The device of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 0.6% (w/w). [0174] Embodiment 59. The device of any one of the preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is between 0.05% (w/w) and 0.3% (w/w). [0175] Embodiment 60. The device of any one of preceding embodiments, wherein a concentration of the hydrophobic ophthalmic agent is less than 0.3% (w/w).
[0176] Embodiment 61. The device of any one of preceding embodiments, wherein the preservative is benzalkonium chloride.
[0177] Embodiment 62. The device of any one of preceding embodiments, where a concentration of the preservative is less than 0.05% (w/w).
[0178] Embodiment 63. The device of any one of preceding embodiments, wherein the polymeric matrix is a polymeric hydrogel.
[0179] Embodiment 64. The device of any one of preceding embodiments, wherein the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co- acrylamide), or a combination thereof.
[0180] Embodiment 65. The device of any one of preceding embodiments, wherein the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2 - acrylamido-2-methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
[0181] Embodiment 66. The device of any one of preceding embodiments, wherein the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP). [0182] Embodiment 67. The device of embodiment 66, wherein the crosslinked polyacrylamide material is isolated in the form of spherical beads.
[0183] Embodiment68. The device of embodiment66 or embodiment 67, wherein the atleast one modifying monomer comprises 2-acrylamido-2 -methylpropane sulfonic acid (AMPS) or 2- sulfoethyl methacrylate (SEM).
[0184] Embodiment 69. The device of any one of preceding embodiments, wherein the solution, suspension, or emulsion further comprises a complexing agent.
[0185] Embodiment 70. The device of embodiment 69, wherein the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
[0186] Embodiment 71. The device of embodiment 69, wherein the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix. [0187] Embodiment 72. The device of embodiment 69, wherein the complexing agent comprises a cyclodextrin.
[0188] Embodiment 73. The device of embodiment 72, wherein the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin.
[0189] Embodiment 74. The device of embodiment 72, wherein the cyclodextrin is at least one of (2-Hydroxypropyl)-a-cyclodextrin, (2-Hydroxypropyl)-P-cyclodextrin, (2 -Hydroxyprop yl)-y- cyclodextrin, a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P- cyclodextrin, methyl-y-cyclodextrin, dimethyl -beta-cyclodextrin, highly sulphated-beta- cyclodextrin, 6-monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin.
[0190] Embodiment 75. The device of embodiment 69, wherein a concentration of the complexing agent is less than 200 micromolar.
[0191] Embodiment 76. The device of any one of preceding embodiments, wherein the polymeric matrix comprises an active matrix component and an inactive matrix component. [0192] Embodiment 77. The device of embodiment 76, wherein the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
[0193] Embodiment 78. The device of embodiment 76 or embodiment 77, wherein the active polymeric matrix component is a polymeric hydrogel.
[0194] Embodiment 79. The device of embodiment 76 or embodiment 77, wherein the inactive polymeric matrix component is a polyolefin.
[0195] Embodiment 80. The device of embodiment 79, wherein the polyolefin is a polyethylene, polypropylene or copolymers thereof.
[0196] Embodiment 81. The device of embodiment 80, wherein the polyolefin is a low-density polyethylene (LDPE).
EXAMPLES
[0197] It is understood that the examples and embodiments described herein are for illustrative purposes only and are not intended to limit the scope of the claimed invention. It is also understood that various modifications or changes in light of the examples and embodiments described herein will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent application cited herein are hereby incorporated by reference in their entirety for all purposes.
[0198] It will be understood that various ophthalmic agents may be used in any aspect of the disclosure provided. It will be understood that various cyclodextrins may be used in any aspect of the disclosure provided to complex the ophthalmic agent in aqueous solution. It will be understood that various preservatives may be used in any aspect of the disclosure provided to render the original solution stable for storage. It will be understood that various porous polymer hydrogel materials may be used in any aspect of the disclosure provided.
Example 1
[0199] A study was conducted to evaluate the ocular hypotensive efficacy and safety of a non - limiting example embodiment of a solution, suspension, or emulsion described herein, TC-002, in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT). TC-002 is 0.005% latanoprost ophthalmic solution preserved in a bottle with benzalkonium chloride, (BAK) where the bottle is configured to prevent BAK from being delivered to the subject. The objective of the study was to demonstrate substantial equivalence of latanoprost ophthalmic solution 0.005% (TC-002) compared to commercially available latanoprost ophthalmic solution 0.005% (LAT) in reducing intraocular pressure (IOP) in participants with glaucoma or ocular hypertension. The secondary objectives of the study were to assess the safety and tolerability of TC-002.
Methods
[0200] The study was conducted according to certain parameters. The study was a Phase 3 study conducted in multiple centers. The study was double-masked between researchers and participants. Details of participants are as follows. Participants had key inclusion criteria for the study. Key inclusion criteria for the study involved adults with bilateral primary open -angle glaucoma (POAG) or OHT with intraocular pressure (IOP) <21 mmHg on a single prostaglandin or analog (PGA) single therapy at visit 1, 28 to 42 days before the commencement of the study. Participants had best-corrected visual acuity (BCVA, Early Treatment of Diabetic Retinopathy Study orETDRS) of +0.6 logMAR or better in each eye. Individuals with other cause glaucoma or multi -drop treatment other than prostaglandins or PGAs were excluded from the study. Participants were assigned to TC-002 or marketed, preserved, latanoprost ophthalmic solution by parallel randomization and were dosed once per day (QD) between 7 and 9 pm for a period of 12 weeks. Dosing was once-daily in both eyes in the evening for 3 months.
[0201] Measurements taken included: IOP and diurnal IOP measured by Goldmann Applanation Tonometry), best corrected visual acuity (BCVA), biomicroscopy, dilated ophthalmoscopy, pachymetry, perimetry, subject-rated drop comfort/tolerability, investigational product levels (in the pharmacokinetic cohort), blood samples, and adverse effects (AE). Diurnal IOP was calculated as the average of 8 :00 AM, 10:00 AM, and 4:00 PM measurements at Weeks 2, 6, and 12. Additionally, changes in a patient-reported outcome questionnaire, an abbreviated Ocular Surface Disease Index (OSD I) were recorded. This questionnaire consisted of 5 questions pertaining: (1) light sensitivity, (2) gritty feeling, (3) pain or soreness, (4) blurred vision, and (5) poor vision. Subjects also recorded their drop administration in a dosing diary to monitor treatment compliance.
Results
[0202] In this large, controlled study, TC-002 was substantially similar and of similar safety to marketed, preserved Iatan oprost. 262 Subjects were enrolled at 24 U. S. Private Practices, of which 254 subjects (97%) completed the study. Approximately 25% of the subjects were Hispanic/ Latino, and approximately 25% were Black. No appreciable differences in demographic or baseline ocular characteristics were observed between the TC-002 and marketed, preserved latanoprost groups. Over the 3 month study, mean intraocular pressure (IOP) reduction from an unmedicated baseline of 24 to 25 mmHg was 6 to 7 mmHg. The primary outcome measure -substantial equivalence of TC-002 to marketed latanoprost, was within 1 .0 mmHg at 8 of the 9 measured time points, and within 1.5 mmHg at all times. Approximately 20% of subjects in each treatment group reported ocular adverse events (AE). The most frequent adverse event (AE) was conjunctival hyperemia. Most events were mild in severity. In a planned subset of the subjects no latanoprost free acid was found in the plasma of the 22 subjects tested.
[0203] Overall, the full analysis for the study included 262 patients with a mean age of 67 years. The age range of the subjects was 33 to 91 years. Mean IOP reduction from an unmedicated baseline of 24 to 25 mmHg was 6 to 7 mmHg (FIG. 2). The results of the study indicate substantial similarity of TC-002 to marketed latanoprost. Mean reduction of IOP was within 1 .0 mmHg at 8 of 9 time points, and within 1.5 mmHg at all time points. Diurnal IOP showed substantial similarity of TC-002 to marketed Iatan oprost. at all 3 time points evaluated at weeks 2, 6, and 12 (FIG. 2). Throughout the study OSDI scores were in the normal range and there were no clinically or statistically significant differences between treatment groups.
Results
[0204] Duringthe study, 26 subjects (19.5%) in the TC-002 group and 24 subjects (18.6%) in the preserved latanoprost group had a total of 35 and 25 ocular adverse effects (AE), respectively, in either eye. The proportion of subjects with an AE related to the investigational product was 9.0% and 10.9% in the TC-002 and preserved latanoprost groups, respectively. At post-baseline visits during weeks 2, 6, and 12, mean change from baseline (CFB) in mean best corrected visual acuity (BCVA) was minimal, ranging from -0.011 to -0.020 logMARin the TC- 002 group and from +0.001 to +0.008 in the preserved latanoprost group .
[0205] The following observations were noted in both treatment groups. Slit-lamp results in the study eye and non-study eye remained relatively stable throughout the study. Ophthalmoscopy showed mean CFB was nominal at each post-baseline visit. Perimetry values remained relatively stable from baseline to the end of the study. The incidence of mild and moderate conjunctival hyperemia increased from baseline in both eyes. On a scale of 0 (comfortable) to 100 (very uncomfortable), subject-rated drop comfort/tolerability, scores were low at Week 2 and held
steady or decreased, indicating improvement, over time. Overall, the mean treatment adherence was 98.7% in this study.
Conclusions
[0206] The results of the study revealed the following. Intraocular pressure (IOP) was within 1.5 mmHG at all 9 time points and 1.0 mmHg at 8 of the 9 time points, for TC-002 and preserved latanoprost indicating substantial equivalence of TC-002 and preserved latanoprost. Diurnal IOP showed substantial similarity at all 3 time points evaluated. TC-002 was generally safe and well tolerated.
Example 2
[0207] A study was conducted to demonstrate the substantial equivalence of timolol ophthalmic solution preserved in a bottle with benzalkonium chloride (BAK) where the bottle is configured to prevent BAK from being delivered to the subject (Ttc) compared to commercially available, preserved timolol in reducing ocular pressure (IOP) in subjects. 40 subjects participated in the study. Prior to commencement of the study, there was up to a 4 week screening period before the baseline measurement of IOP was collected. After the baseline measurement was collected the subjects were randomized and separated into groups. Of the 40 subjects participatingin the study, 30 subjects were administered Ttc and 10 subjects were administered commercially available, preserved timolol. After commencement of the study, IOP was measured at day 7 and 28.
Results
[0208] No drug related adverse effects were observed during the study. The mean baseline measurement for subjects in both groups was nearly 24 mmHg. For the first measurement on day 7, the group administered Ttc demonstrated a mean IOP of about 18.9 mmHg compared to the group administered commercially available, preserved timolol where the mean IOP was about 19.9 mmHg. For the second measurement on day 28, the mean IOP was similar. In the group administered Ttc, the mean IOP was about 19.2 mmHg. The group administered commercially available, preserved timolol was about 20 mmHg. Both Ttc and commercially available, preserved latanoprost maintained IOP below the mean IOP collected before randomization. In particular, Ttc lowered IOP by about 1 mmHg more than commercially available, preserved timolol. Both Ttc and commercially available, preserved latanoprost maintained IOP under about 20 mmHg over the study period. In particular, Ttc maintained IOP under 19.5 mmHg overthe study period. A graph summarizing the data is found in FIG. 3B.
Example 3
[0209] A study was conducted to demonstrate the substantial equivalence of a non-limiting example embodiment of a solution, suspension, or emulsion described herein, TC-002 compared
to commercially available, BAK preserved latanoprost ophthalmic solution 0.005% in reducing ocular pressure (IOP) in subjects. TC-002 is 0.005% latanoprost ophthalmic solution preserved in a bottle with benzalkonium chloride, (BAK) where the bottle is configured to prevent BAK from being delivered to the subject. 15 subjects participated in the study. Day 1 of the study involved screening the subjects and randomization of the subjects. After randomization, the 15 subjects were separated into groups. Of the 15 subjects participatingin the study, 10 subjects were administered TC-002 and 5 subjects were administered commercially available, BAK preserved latanoprost ophthalmic solution 0.005%. On day 1 of the study, a baseline measurement of IOP was measured in the right eye (OD) and left eye (OS) of subjects in both groups at 10 am. Over a 27 day period the 10 subjects in the TC-002 group were administered TC-002 once daily and the 5 subjects in the commercially available, BAK preserved latanoprost ophthalmic solution 0.005% group were administered commercially available, BAK preserved latanoprost ophthalmic solution 0.005% once daily. In addition to the baseline measured on day 1 , IOP of all subjects was measured in the right eye (OD) and the left eye (OS) at 10 AM on days 8, 15, and 27.
Results
[0210] The mean baseline IOP measurement for the TC-002 group was 18.1 mmHG(OD) and 18.0 (OS). The mean baseline IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 17.0 (OD) and 15.8 mmHg (OS). The mean day 8 IOP measurement for the TC-002 group was 17.8 mmHg (OD), a decrease of 0.3 mmHg from the baseline measurement and 18.2 mmHg (OS), an increase of .2 mmHg from the baseline measurement. The mean day 8 IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 16.4 mmHg (OD), a decrease of 0.6 mmHg from the baseline measurement and 17.2 mmHg (OS), an increase of 1 .4 mmHg from the baseline measurement. The mean day 15 IOP measurement for the TC-002 group was 18.7 mmHg (OD), an increase of 0.6 mmHg from the baseline measurement and 19.5 mmHg (OS), an increase of 1.5 mmHg from the baseline measurement. The mean day 15 IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 18 mmHg (OD), an increase of 1 .0 mmHg from the baseline measurement and 16.8 mmHg (OS), an increase of 1.0 mmHg from the baseline measurement. The mean day 27 IOP measurement for the TC-002 group was 16.6 mmHg (OD), a decrease of 1.5 mmHg from the baseline measurement and 17.0 mmHg (OS), an decrease of 1.0 mmHg from the baseline measurement. The mean day 27 IOP measurement for the commercially available, BAK preserved latanoprost ophthalmic solution group was 18 mmHg (OD), an increase of 1.0 mmHg from the baseline measurement and 17.4 mmHg (OS), an increase of 1.6 mmHg from the baseline measurement.
Over the nearly four week period, both groups demonstrated maintained reduced IOP close to the baseline. As discussed herein, the normal range of IOP is between 10 and 1 mmHg, met by all groups for each measurement. Furthermore, the maintenance in IOP between the commercially available, BAK preserved latanoprost ophthalmic solution group and the TC-002 group indicated substantial equivalence between the ophthalmic solutions. The data and a graph summarizing the data can be found in FIGS. 4B-4D.
Example 4
[0211] An example method of demonstrating the substantial of the activity of commercially available preserved timolol to a solution, suspension, or emulsion comprising the ophthalmic agent timolol and a preservative comprising benzalkonium chloride wherein the activity is reducing intraocular pressure (IOP) in subjects. Such a method may be achieved by measuring the reduction of IOP in a subject administered commercially available, preserved timolol solution. Furthermore, measuring the reduction of IOP in a subject administered a solution, suspension, or emulsion comprising the ophthalmic agent timolol and a preservative comprising benzalkonium chloride wherein the solution, suspension, or emulsion is passed through a polymeric matrix selectively removing the preservative from the solution, suspension, or emulsion. Comparison of the two measurements may demonstrate their substantial equivalence in reducing IOP in subjects.
[0212] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1. A method for providing a hydrophobic ophthalmic agent comprising: providing a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and providing a polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative i s selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
2. A method for providing an ophthalmic agent comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
3. A method for delivering a hydrophobic ophthalmic agent to an eye of a subject to reduce intraocular pressure comprising: applying pressure to a compressible bottle comprising an extended outlet, a polymeric matrix within the extended outlet, and a reservoir holding a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative; and forming a drop comprising the solution, suspension, or emulsion after passing through the polymeric matrix, the polymeric matrix configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
4. The method of any one of preceding claims, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains at least 50%, 60%, 70%, 80%, or 90% of an activity of the hydrophobic ophthalmic agent as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
5. The method of any one of preceding claims, wherein the polymeric matrix is configured such that the solution, suspension, or emulsion after passing through the polymeric matrix maintains less than 50%, 40%, 30%, 20%, or 10% of the preservative as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
6. The method of any one of preceding claims, wherein the activity of the hydrophobic ophthalmic agent comprises reducing an intraocular pressure (IOP) of an eye.
7. The method of any one of preceding claims, wherein the activity of the hydrophobic ophthalmic agent comprises treating ocular hypertension, or open angle glaucoma, or a combination thereof.
8. The method of any one of preceding claims, wherein the activity of the hydrophobic ophthalmic agent comprises improving visual acuity.
9. The method of any one of preceding claims, wherein the reducing IOP comprises reducing IOP by at least 1, 2, 3, 4, 5, or 6 mmHg.
10. The method of any one of preceding claims, wherein the reducing IOP comprises reducing IOP to 21 , 20, 19, or 18 mmHg or lower.
11 . The method of any one of the preceding claims, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
12. The method of any one of preceding claims, wherein the solution, suspension, or emulsion after passing through the polymeric matrix reduces IOP within 2 mmHg as compared to the solution, suspension, or emulsion without passing through the polymeric matrix.
13. The method of any one of the preceding claims, wherein the activity of the hydrophobic ophthalmic agent comprises maintaining the intraocular pressure (IOP) of an eye below at least 25, 24, 23, 22, or 21 mmHg.
14. The method of any one of preceding claims, wherein the hydrophobic ophthalmic agent comprises latanoprost, timolol, brinzolamide, brimonidine, travoprost, bimatoprost, netarsudil, latanoprostbunod, dorzolamide, or aceclidine, or a combination thereof.
15. The method of any one of preceding claims, wherein the hydrophobic ophthalmic agent comprises latanoprost, bimatoprost, dexamethasone, cyclosporine, travoprost, or a prostaglandin analog drug, or a combination thereof.
16. The method of any one of preceding claims, wherein a concentration of the hydrophobic ophthalmic agent is less than 500 millimolar.
17. The method of any one of the preceding claims, wherein a concentration of the hydrophobic ophthalmic agent is between 0.01% (w/w) and 1.5% (w/w).
18. The method of any one of preceding claims, wherein a concentration of the hydrophobic ophthalmic agentis less than 0.3% (w/w).
19. The method of any one of preceding claims, wherein the preservative is benzalkonium chloride.
20. The method of any one of preceding claims, where a concentration of the preservative is less than 0.05% (w/w).
21. The method of any one of preceding claims, wherein the polymeric matrix is a polymeric hydrogel.
22. The method of any one of preceding claims, wherein the polymeric matrix comprises crosslinked polyvinylpyrrolidone, crosslinked polyethylene oxide, crosslinked polyacrylamides, crosslinked copolymers of methacrylic acid, polyacrylic acid, or copolymers selected from poly (acrylic acid-co-acrylamide), or poly (methacrylic acid-co-acrylamide), or a combination thereof.
23. The method of any one of preceding claims, wherein the polymeric matrix comprises a hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR
351 , or SR9035 ; and the crosslinked polyacrylamide is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2 -methylpropane sulfonic acid (AMPS), 2 -sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
24. The method of any one of preceding claims, wherein the polymeric matrix is hydrogel prepared from polyacrylamide crosslinked with at least one crosslinking monomer selected from N,N’-methylenebis(acrylamide) (MB AM), triacrylamido triazine (TATZ), SR 351, or SR9035; the crosslinked polyacrylamide material is isolated; and the crosslinked polyacrylamide material is modified with at least one modifying monomer selected from methyl methacrylate (MAA), 2-acrylamido-2-methylpropane sulfonic acid (AMPS), 2-sulfoethyl methacrylate (SEM), acrylic acid (AA), orvinylphosphonic acid (VP).
25. The method of claim 24, wherein the crosslinked polyacrylamide material is isolated in the form of spherical beads.
26. The method of claim 24 or claim 25, wherein the at least one modifying monomer comprises 2-acrylamido-2-methylpropane sulfonic acid (AMPS) or 2-sulfoethyl methacrylate (SEM).
27. The method of any one of preceding claims, wherein the solution, suspension, or emulsion further comprises a complexing agent.
28. The method of claim 27, wherein the complexing agent and the hydrophobic ophthalmic agent form an inclusion compound.
29. The method of claim 27, wherein the complexing agent is configured to reduce an affinity of the hydrophobic ophthalmic agent for the polymeric matrix.
30. The method of claim 27, wherein the complexing agent comprises a cyclodextrin.
31. The method of claim 30, wherein the cyclodextrin is sized to host the hydrophobic ophthalmic agent within a hydrophobic interior of the cyclodextrin.
32. The method of claim 30, wherein the cyclodextrin is at least one of (2-Hydroxypropyl)- a-cyclodextrin, (2-Hydroxypropyl)-P-cyclodextrin, (2-Hydroxypropyl)-y-cyclodextrin, a- cyclodextrin, P -cyclodextrin, y-cyclodextrin, methyl-a-cyclodextrin, methyl-P-cyclodextrin, methyl-y-cyclodextrin, dimethyl-beta-cyclodextrin, highly sulphated-beta-cyclodextrin, 6- monodeoxy-6-N-mono(3 -hydroxy )propylamino-beta-cyclodextrin, or a randomly or selectively substituted alpha, beta or gamma cyclodextrin.
33. The method of claim 27, wherein a concentration of the complexing agent is less than 200 micromolar.
34. The method of any one of preceding claims, wherein the polymeric matrix comprises an active matrix component and an inactive matrix component.
35. The method of claim 34, wherein the inactive matrix component has substantially no affinity for the hydrophobic ophthalmic agent or the preservative.
36. The method of claim 34 or claim 35, wherein the active polymeric matrix component is a polymeric hydrogel.
37. The method of claim 34 or claim 35, wherein the inactive polymeric matrix component is a polyolefin.
38. The method of claim 37, wherein the polyolefin is a polyethylene, polypropylene or copolymers thereof.
39. The method of claim 38, wherein the polyolefin is a low-density polyethylene (LDPE).
40. A multi-dosing delivery device for dispensing a hydrophobic ophthalmic agent, the device comprising: a bottle having an extended outlet; a polymeric matrix dispensed within the extended outlet; and a reservoir configured to hold a solution, suspension, or emulsion comprising the hydrophobic ophthalmic agent and a preservative, wherein the polymeric matrix is configured such that an activity of the hydrophobic ophthalmic agent is substantially maintained and the preservative is selectively removed in the solution, suspension, or emulsion after passing through the polymeric matrix.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263331142P | 2022-04-14 | 2022-04-14 | |
US63/331,142 | 2022-04-14 | ||
US202363449538P | 2023-03-02 | 2023-03-02 | |
US63/449,538 | 2023-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023201315A2 true WO2023201315A2 (en) | 2023-10-19 |
WO2023201315A3 WO2023201315A3 (en) | 2023-11-30 |
Family
ID=88330406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/065750 WO2023201315A2 (en) | 2022-04-14 | 2023-04-13 | Ophthalmic agent in preservative removal device |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023201315A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
CN106572941B (en) * | 2014-08-13 | 2020-06-23 | 佛罗里达大学研究基金会股份有限公司 | Removal of preservatives from ophthalmic solutions |
EP3548000B1 (en) * | 2017-05-11 | 2021-11-10 | Vyluma Inc. | Atropine pharmaceutical compositions |
US20200246222A1 (en) * | 2019-02-06 | 2020-08-06 | TearClear Corp. | Systems and Methods for Preservative Removal from Ophthalmic Formulations Comprising Complexing Agents |
-
2023
- 2023-04-13 WO PCT/US2023/065750 patent/WO2023201315A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023201315A3 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7358221B2 (en) | Compositions and methods for treating presbyopia | |
US11045390B2 (en) | Systems and methods for delivery of a therapeutic agent | |
US20200246222A1 (en) | Systems and Methods for Preservative Removal from Ophthalmic Formulations Comprising Complexing Agents | |
AU2016280616B2 (en) | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye | |
US20220409430A1 (en) | Systems and methods for preservative removal from ophthalmic formulations | |
WO2017066052A1 (en) | Formulations and methods for treating high intraocular pressure | |
US11564832B2 (en) | Device and methods for flow control of ophthalmic formulations | |
WO2023201315A2 (en) | Ophthalmic agent in preservative removal device | |
US11963906B2 (en) | Devices and methods for flow control of ophthalmic formulations | |
TW202333700A (en) | Compositions and methods for the treatment of eye conditions | |
WO2015048526A1 (en) | Treating ocular pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23789161 Country of ref document: EP Kind code of ref document: A2 |